joris
IMMP · Immutep Limited

Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy

Cleared (data check passed)

Resectable, non-metastatic, FNCLCC grade 2-3 soft tissue sarcoma of the extremities, girdles or superficial trunk, primary tumour larger than 5 cm or any locally recurrent tumour, given before surgery

BPIQ drug id 17452 · efti-pembrolizumab-soft-tissue-sarcoma

Analysis as of 2026-10-17 Framework v6.2.0 NCT06128863
Contaminated Another program's result is due close to this one, so a price move cannot be tied to this event alone.
  • IMP761 (LAG-3 agonist) 2026-12-31 · BPIQ id 18203 · not yet analysed (BPIQ data row): overlaps, a date the company has given

Readout window opens 2026-10-19. Re-checks done: T-5, T-1 (T-5, T-2 and T-1 mean 5, 2 and 1 months before the window opens).

Readout window

When the result of this big event is expected, and what each source says

Our expected window (earliest to latest date) Most likely date Checked against the original source Not checked Estimate from a web search
Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026Q4 2026 Window Our expected window: 2026-10-19 to 2026-10-19. Most likely date: 2026-10-19. Basis: One moment discloses the numbers: Immutep stated on 2026-07-24 that the full abstract publishes on the ESMO Congress 2026 website on Monday 19 October 2026, online at 00:05 CEST (18:05 on Sunday 18 October in New York, so the first US session able to react is 2026-10-19). The ePoster 3788eP shown during the congress on 23-27 October carries the same content and is not a second readout. Precision is DAY because the company names the day; confidence is HIGH because the trial is complete, the abstract is accepted and the date is a publisher's calendar. Corrected after the first lock and kept from the 2026-08-19 version: the window was first written with latest 2026-10-27, which counted the congress tail twice; it was narrowed rather than relabelled. Most likely date: 2026-10-19BPIQBPIQ: 2026-10-19 (“October 19, 2026”). Evidence tag: VERIFIED - BPIQ fetch_company_drugs 2026-10-17. catalyst_date_text names a day, so catalyst_date_is_exact is true. Unchanged since 2026-08-19.CT.govCT.gov: 2025-04-30. Evidence tag: VERIFIED - CT.gov get_trial_details NCT06128863, 2026-10-17. Dates the primary readout, which happened in May 2025, so it bounds nothing about this secondary analysis. Study completion 2027-04-30 covers the 24-month follow-up.CompanyCompany: 2026-10-19. Evidence tag: VERIFIED - Immutep release 2026-07-24. Abstract 'Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) - results from EFTISARC-NEO trial', ePoster 3788eP, first author Pawel Teterycz; 'Abstract online: Monday, 19 October 2026 at 00:05 CEST'. Reaffirmed 2026-07-30; no later release moved it.CongressCongress: 2026-10-23/2026-10-27. Evidence tag: VERIFIED - data/congresses.json, confirmed against esmo.org. A legitimate congress source because the company said it will present there. The ePoster's display day is not disclosed.ModelledModelled: 2025-06-30/2025-08-31. Evidence tag: UNVERIFIED - modelled, default lag. Uninformative and recorded anyway: the method dates the primary readout, which came on 2025-05-27. Separately, 2025-04-30 against 2025-05-27 is a confirmed 27-day lag from two primary sources; data/benchmarks/readout-lag.json is outside this lane and was not touched.

5 of 5 sources we checked gave a date. One moment discloses the numbers: Immutep stated on 2026-07-24 that the full abstract publishes on the ESMO Congress 2026 website on Monday 19 October 2026, online at 00:05 CEST (18:05 on Sunday 18 October in New York, so the first US session able to react is 2026-10-19). The ePoster 3788eP shown during the congress on 23-27 October carries the same content and is not a second readout. Precision is DAY because the company names the day; confidence is HIGH because the trial is complete, the abstract is accepted and the date is a publisher's calendar. Corrected after the first lock and kept from the 2026-08-19 version: the window was first written with latest 2026-10-27, which counted the congress tail twice; it was narrowed rather than relabelled. (BPIQ is a biotech data service. CT.gov is ClinicalTrials.gov, the US trial registry.)

The sources agree.

Table view (the same information as the chart, as text)
SourceDate givenEvidence tagNote
BPIQ2026-10-19VERIFIED - BPIQ fetch_company_drugs 2026-10-17catalyst_date_text names a day, so catalyst_date_is_exact is true. Unchanged since 2026-08-19.
CT.gov2025-04-30VERIFIED - CT.gov get_trial_details NCT06128863, 2026-10-17Dates the primary readout, which happened in May 2025, so it bounds nothing about this secondary analysis. Study completion 2027-04-30 covers the 24-month follow-up.
Company2026-10-19VERIFIED - Immutep release 2026-07-24Abstract 'Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) - results from EFTISARC-NEO trial', ePoster 3788eP, first author Pawel Teterycz; 'Abstract online: Monday, 19 October 2026 at 00:05 CEST'. Reaffirmed 2026-07-30; no later release moved it.
Congress2026-10-23/2026-10-27VERIFIED - data/congresses.json, confirmed against esmo.orgA legitimate congress source because the company said it will present there. The ePoster's display day is not disclosed.
Modelled2025-06-30/2025-08-31UNVERIFIED - modelled, default lagUninformative and recorded anyway: the method dates the primary readout, which came on 2025-05-27. Separately, 2025-04-30 against 2025-05-27 is a confirmed 27-day lag from two primary sources; data/benchmarks/readout-lag.json is outside this lane and was not touched.

Verdict

A written summary that is not scored. The scored predictions below are the official prediction.

What I would do (buy, watch, avoid or no view) watch

Why

The date is certain and the event carries little information. What decides this program is whether a randomised sarcoma trial is designed and funded for 2H CY2027 and whether the 200 L product behaves like the product that worked. The stock already trades 27% below its cash floor.

What would change this

Upside: a funded or partnered randomised STS trial, or a completed root cause analysis restoring confidence in the product. Downside: a reported meaningful deterioration in quality of life, or an equity raise this far below cash.

What to watch

  • 2026-10-19 00:05 CEST: full abstract on the ESMO 2026 website
  • 2026-10-23 to 2026-10-27: ESMO 2026, ePoster 3788eP and any release
  • By 2026-10-31: September-quarter activities report and FY26 Form 20-F
  • Undated: completion of the TACTI-004 root cause analysis; IMP761 update (H2 2026)
  • 2026-11-27: annual general meeting
  • 2027-04-30: EFTISARC-NEO study completion

Prediction

The outcome and the stock direction are scored separately

the probability, share price at the time and stock scenarios for this prediction. It was locked before those fields existed. We do not rebuild them from text written to an older standard, because that would damage the record we use to check how well our confidence matches reality. So these fields are left as null (empty): runup.

Outcome (the trial or regulator decision) modelled
Positive
85% [72–92]

The probability that settlement_criteria.positive_definition is met. High for four reasons: no grade 3+ toxicity attributed to efti or pembrolizumab in EFTISARC-NEO; AIPAC (Clin Cancer Res 2024, DOI 10.1158/1078-0432.CCR-23-1173) found EORTC QLQ-C30/-B23 global health status sustained on efti and deteriorated on placebo; the regimen adds injections to visits already scheduled; and the sponsor chose to submit and announce the abstract (2026-07-24). Capped below 90 for three: the endpoint is not registered on NCT06128863; the instrument is undisclosed; and nine weeks of therapy around radiotherapy and surgery can produce a real dip at one timepoint, which in 38 patients could reach statistical significance. No evidence in the 2026-10-17 sweep moved the figure from the 2026-08-19 value. No third party has published a probability on this event.

Stock direction (share price) price when locked $3.20 · 2026-10-16
$2.30–$3.00 miss positive $3.05–$4.00
Scenario Low High Anchors (evidence behind the range) How it was worked out
Positive $3.05 $4.00
  • VERIFIED This ticker's own past moves: median event-window move across the eight clean, non-registrational data events in company.md C.7 (2024-11-14, 2025-05-27, 2025-10-20, 2025-11-13, 2025-12-22, 2026-05-28, 2026-06-04, 2026-07-13), implying US$3.26 — +1.81%
  • VERIFIED Cash floor at readout.window.likeliest 2026-10-19: (US$47,927,374 cash - US$5,225,091 debt-like items - US$8,350,560 x 1.22 quarters) / 7,452,053 ADS-equivalents — 4.37
Low edge US$3.05 is the price if the abstract just meets positive_definition, the 'met expectations' bucket of framework/07-benchmarks.md: 5% below spot, because three of this ticker's last four positive data events closed lower. High edge US$4.00 is the 'significantly exceeded' bucket - quality of life improved, with a release adding follow-up or a funded next step - and stops below the US$4.37 cash floor. The ticker's maximum, +80.65% on the 2026-04-15 orphan designation, was a regulatory fact and is not used. The +12% Phase 2 class average [WEB ESTIMATE - IQVIA 2024] is not applied at full weight, because this is a secondary analysis, not a primary readout.
Miss $2.30 $3.00
  • VERIFIED Cash floor at readout.window.likeliest 2026-10-19, as on the positive row — 4.37
  • VERIFIED This ticker's own past moves on disappointing news: the worst comparable data-event window (2026-06-04, -7.23%, implying US$2.97) and the ten-session reaction to the 2026-09-11 strategy release (0.37 to 0.26 on the old basis, -30%, implying US$2.24) — -7.23% / -30%
The whole row sits below the US$4.37 cash floor, for three stated reasons: the floor counts burn only to 2026-10-19 while the company plans to spend its cash on efti trials into 2028 and returns none; the market already values the company 27% below the floor; and the ADS line has slid 32% since the ratio change took effect. A meaningful deterioration in quality of life would be new negative information about the one property this regimen's case rests on, in one of the two indications left. The miss cuts deeper (to -28%) than the positive lifts (to +25%), as the Phase 2 negative-to-positive ratio of 1.3 suggests [WEB ESTIMATE - IQVIA 2024].
$3.39+6.1% modelled estimate

+2.5% to +8.0% compared with the current price, across our 72–92% range of probabilities. We cannot tell yet whether it is above or below the current price.

probability_pct (85%) applied to the midpoint of each scenario range: 0.85 x US$3.525 + 0.15 x US$2.65 = US$3.394, against a spot of US$3.20

No edge how sure we are of the direction None

MATERIALITY (rule 27): company.md C.2 records this program as meaningful at the programme level and immaterial at the event level; the call follows the event. ATTRIBUTION (rule 36): CONTAMINATED by IMP761's H2 2026 window (gap 0 days, confirmed), with the September-quarter activities report and the FY26 Form 20-F both due by 2026-10-31, inside the window. THE BAND TEST DECIDES (rule 42): our band [72, 92] overlaps the break-even range [20.0, 120.0], so callFromBands returns no-edge whatever the evidence. The expected value sits +6.05% above spot; that divergence is the gap between our 85% and the 62.9% break-even point times the spread of the midpoints, and rule 42 does not let a point gap override an overlapping band. The range's top exceeds 100% because the positive low (US$3.05) sits below spot: if just meeting the bar draws the sell-the-news reaction this ticker has shown (2025-10-20 -1.7%, 2026-06-04 -7.2%, 2026-07-24 -2.6%), even a certain positive would not support today's price. UNIT BASIS: every price here is per ADS on the 1 ADS = 200 ordinary basis effective 2026-09-28; the superseded record's US$0.40 spot equals US$8.00 on this basis. Spot is the settled close of 2026-10-16 from data/prices/IMMP.json, not an intraday figure.

2026-10-19 → 2026-11-03 · Opens when the full abstract publishes on the ESMO Congress 2026 website (2026-10-19 00:05 CEST, before the first US and ASX sessions that day) and closes one week after the congress ends (2026-10-27), covering the abstract, ePoster 3788eP and any accompanying release. Anchored on readout.window, not catalyst_date (rule 23).

break-even chance of success from our own price ranges: 62.9% (range 20–120%) · our band overlaps it · highest sensible price from sales potential: 70.7

published base rate for this phase: 24.6% (BIO 2021 (BIO/Informa/QLS), Figure 2, p. 7, Oncology, via lib/success-rates.mjs baseRate (phase2, oncology, modality other; area-level fallback); identical to asset_evaluation.pos.base_rate)

Rationale

A T-1 refresh (full company-tier and program-tier sweep on 2026-10-17), not a re-lock. It supersedes IMMP-17452-2026-08-19. OUTCOME stays positive at 85% (72-92): this catalyst asks whether patients felt meaningfully worse, not whether the drug works, and nothing in the sweep moved that judgement; the base rate it names (24.6%, BIO 2021 Phase 2 oncology to Phase 3) measures a different event. STOCK is no-edge by rule 42: our band [72, 92] overlaps the break-even range [20.0, 120.0]. The stock trades at US$3.20, 27% below a US$4.37 cash floor, after a 60% fall since 2026-08-19 (US$8.00 on today's basis): first on the 2026-09-11 strategy release (next trials 2H CY2027, a manufacturing finding behind the Phase 3 failure), then after the 2026-09-28 change from 1 ADS = 10 to 1 ADS = 200 ordinary shares. Attribution is CONTAMINATED by IMP761 and by a quarterly report and the 20-F due inside the window. RUN-UP is not carried over, and this is not rule 39: date_confidence would be 100, but every permitted exit (T-5, T-2, T-1 trading days before 2026-10-19 resolve to 2026-10-12, 2026-10-15 and 2026-10-16) falls on or before the entry's own price date, the 2026-10-16 close, so no position can be formed. The 2026-08-19 record's own run-up call remains as history and needs spot_scale 20 at settlement.

Locked (cannot be changed) Awaiting the result Prediction dated 2026-10-17

Prediction history

2 predictions locked on this program, with the changes between one and the next

Every prediction ever locked on this program, oldest first. A refresh does not edit an old prediction. It adds a new one that replaces ("supersedes") the old one. Each earlier prediction is kept exactly as written, because it shows what we believed before the outcome was known. It is not an out-of-date draft that needs fixing. A column marked "moved" shows a value that changed since the previous prediction.

We re-check each program at set points: 5, 2 and 1 months before the expected result. Each column is labelled with the checkpoint it fell in. The checkpoint is judged against the readout window that prediction itself assumed. “Ad-hoc” means there was no readout window yet, so no checkpoint could be set. This applies to every program in this corpus today, so expect to see it below. It means the refreshes that add a window are still waiting to be done. It does not mean this table has a gap.

Field
2026-08-19 IMMP-17452-2026-08-19 T-5 Superseded
2026-10-17 IMMP-17452-2026-10-17 T-1 Live
Probability of a good outcome 85% 85%
Probability range 72–92% 72–92%
Stock-call window (dates the stock call covers) 2026-10-19 → 2026-11-03 2026-10-19 → 2026-11-03 moved
Share price when locked $0.40 2026-08-19 $3.20 2026-10-16 moved
Expected share price $0.40 (-0.9%) $3.39 (+6.1%) moved
Share price ranges (positive result and miss) positive result $0.36–$0.46 · miss $0.28–$0.36 positive result $3.05–$4.00 · miss $2.30–$3.00 moved
Readout window 2026-10-19 → 2026-10-19 most likely 2026-10-19 2026-10-19 → 2026-10-19 most likely 2026-10-19
Run-up score 55 · move -10–15% No run-up call locked moved

Catalyst

The binary event being scored

Name
EFTISARC-NEO health-related quality-of-life data, ESMO Congress 2026 abstract publication and ePoster
Catalyst Date
2026-10-19
Catalyst Date Text
October 19, 2026
Catalyst Date Is Exact
Yes
Nct
NCT06128863
Date Slips
0

Clinical

Trial history and readouts

Moa
A dimeric fusion of the LAG-3 extracellular domains with an IgG1 Fc tail that binds MHC class II on antigen-presenting cells and switches them on; 30 mg subcutaneously every 2 weeks.
Regimen In This Trial
Efti and pembrolizumab weeks 1-9; radiotherapy weeks 2-6 (5 days a week); surgery weeks 11-12; 24-month follow-up.
Primary Endpoint Result
Median 51.5% tumour hyalinization/fibrosis (n=38) against a 35% target and about 15% historically with radiotherapy alone.
What This Catalyst Actually Is
An HRQoL analysis of the same 40 patients, not a registered outcome measure, presented as ePoster 3788eP at ESMO 2026; abstract online 2026-10-19 00:05 CEST.
Honest Scientific Risk
Single-arm: the effect cannot be separated from the pembrolizumab-plus-radiotherapy backbone, which works on its own (SARC032)., Surrogate endpoint with no regulatory acceptance in sarcoma., The catalyst's endpoint is unregistered and its instrument undisclosed., Product comparability: 2,000 L product differs from 200 L product (2026-09-11); the scale used in EFTISARC-NEO is undisclosed.
Evidence Quality
Target Validation
3
Mechanism And Target Engagement
6
Translational Biomarkers
4
Clinical Effect Against Standard Of Care
4
Consistency And Replication
4
Therapeutic Window And Safety
8
Data Transparency And Expert View
4
Endpoints
Primary Registered
Pathologic response, measured as percent tumour hyalinization/fibrosis at the time of definitive surgical resection. Scale 0-100% of the specimen; higher is better. No formally established MCID; the sarcoma literature conventionally treats >=35% as a pathologic response and the historical median with radiotherapy alone is about 15%.
Catalyst Endpoint
Health-related quality of life - what patients report about pain, fatigue, physical function and overall wellbeing. Instrument NOT disclosed. If it is the EORTC QLQ-C30, global health status runs 0-100, higher better, with roughly 10 points conventionally treated as clinically meaningful. NOT A REGISTERED OUTCOME MEASURE on this trial.
Secondary Registered
Number of participants experiencing adverse events, graded on CTCAE v5.0, Number of participants completing neoadjuvant therapy and reaching curative surgery per protocol, Disease-free survival (DFS) from curative surgery to first recurrence or death, Local recurrence-free survival (LRFS), Distant metastasis-free survival (DMFS) - the endpoint the immune hypothesis actually predicts, on the SARC032 reading that immunotherapy in sarcoma acts on micrometastatic disease, Overall survival (OS) from curative surgery, Objective response rate by RECIST 1.1 before surgery - reported as 19.0%, low relative to the 71.4% pathologic response rate because sarcomas often turn to scar without shrinking on imaging
Why This Combination
Soft tissue sarcomas are immune-cold: few mutations, few infiltrating T cells, which is why checkpoint drugs alone work poorly in them. The regimen attacks that from three directions. Radiotherapy kills tumour cells and releases antigen; efti switches on the cells whose job is to pick that antigen up; pembrolizumab removes the PD-1 brake so the T cells that arrive can act.

Competitive landscape

Comparators and benchmarks

Mechanism Differentiation
HIGH on novelty, and it is genuine. Eftilagimod alfa is the only soluble MHC class II agonist in clinical development anywhere. Every other LAG-3 drug - relatlimab, tebotelimab, favezelimab - blocks the pathway; this one activates it from the other end. It is not a variation on a competitor, it is the only member of its class.
Timeline Advantage
LOW - lagging, and by more than 12 months. SARC032 (pembrolizumab added to neoadjuvant radiotherapy, randomised, n~127) is a completed trial with a met primary endpoint on disease-free survival, a Lancet publication and NCCN recognition. EFTISARC-NEO is a 40-patient single-arm study at one site with no randomised comparator, no publication and no funded registrational trial. Efti is not ahead of the competition here; it is trying to add to it.
Proof Of Concept
MEDIUM. n=38 evaluable, squarely in the matrix's middle box. Statistically significant with a large effect against the historical control, but uncontrolled.
Ip Protection
MEDIUM. Composition-of-matter on the molecule would be old - IMP321 dates to the mid-2000s - and no expiry was confirmed. What WAS confirmed is a fourth US patent granted 2026-07-14 covering treatment of cancer with eftilagimod alfa in combination with a PD-1 pathway inhibitor, running to 2036: method-of-use, but squarely over the combination this program uses. Orphan Drug Designation would add seven years of US market exclusivity on approval.
Other Neoadjuvant Immunotherapy In Sts
SARC032 (pembrolizumab + RT, met DFS, NCCN-recognised); a randomised Phase 2 of neoadjuvant nivolumab or nivolumab plus ipilimumab with concurrent RT in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma, reporting median pathological response of 90.0% for UPS with nivolumab plus RT; and NEXIS (durvalumab plus tremelimumab with external beam radiation). [WEB ESTIMATE - competitive web search, 2026-08-19]
Where It Wins
On being the only drug of its kind, in a disease where the immune approach has just been shown to work and where the obvious next question is how to make it work better. It also wins, uniquely among efti's indications, on holding a regulatory designation.
The Single Fact The Thesis Rests On
That a 51.5% median hyalinization in 38 uncontrolled patients reflects something eftilagimod alfa ADDED, rather than what pembrolizumab plus radiotherapy does on its own. Nothing in the evidence base separates those two readings, and no trial that could separate them is funded.
Sarc032 Correction
The 2026-08-19 version called SARC032 a 'randomised Phase 3' and dated its Lancet paper 2024-09-14. The Lancet abstract describes 'an open-label, randomised clinical trial' with 143 patients randomised (127 analysed), and PubMed dates it 2024-11-12.
Scores
Mechanism Differentiation
8
Timing Against Competitors
2
Clinical Data Against Competitors
5
IP And Exclusivity
5

Treatment algorithm

Standard of care and where the asset fits

Step 1 Diagnosis
Imaging, biopsy and FNCLCC 1-3 grading. Small, superficial or low-grade tumours go straight to surgery and never reach this trial's population.
Step 2 Neoadjuvant Radiotherapy
For large, deep, grade 2-3 tumours, roughly five weeks of radiotherapy before the operation. Standard and long-established. This is what the historical 15% hyalinization figure comes from.
Step 3 Neoadjuvant Chemotherapy
An anthracycline with ifosfamide, in some centres and some histologies. Contested and not universal.
Step 4 Pembrolizumab Added
WHERE THIS DRUG WOULD BE GIVEN, AS A THIRD AGENT. Following SARC032, adding pembrolizumab to neoadjuvant radiotherapy improved disease-free survival and is now recognised in NCCN guidance for the relevant histologies. [WEB ESTIMATE - SARC032 Lancet publication and NCCN recognition via web search, 2026-08-19]
Step 5 Surgery
Wide surgical excision five to six weeks after radiotherapy ends.
Step 6 Relapse
Treated systemically with doxorubicin-based regimens then later lines. Roughly half of high-risk patients relapse, and most relapses are distant rather than local.
Where Efti Fits
Step 4, as a third drug. It displaces nothing. It is added on top of a two-drug regimen that itself only recently became standard - and on top of the SPECIFIC regimen whose benefit was demonstrated without it. That is a harder commercial position than 'first in a setting where nothing works': the incumbent here is not an absence, it is a randomised trial with a met endpoint.

Intellectual property

Exclusivity and royalty burden

Combination Patent
Fourth United States patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor, granted and announced 2026-07-14, running to 2036. Method-of-use rather than composition-of-matter, but squarely over the combination this program uses. [VERIFIED - Immutep press release 2026-07-14]
Composition Of Matter
NOT ESTABLISHED. IMP321 dates to the mid-2000s so any composition-of-matter term would be old, and no expiry was confirmed from a patent record or a filing this session. Recorded as unknown rather than assumed. [UNVERIFIED]
Orphan Exclusivity
FDA Orphan Drug Designation granted 2026-04-15 for eftilagimod alfa in soft tissue sarcoma: seven years of US market exclusivity for the designated indication IF the drug is approved, plus application-fee exemption and tax credits on qualifying US trial costs. It grants nothing about approvability and involves no efficacy judgement. [VERIFIED - Immutep press release 2026-04-15]
Other Designations
No Breakthrough Therapy, Fast Track, Priority Review or Special Protocol Assessment was found for this indication in the press feed or the EDGAR filings feed. [UNVERIFIED - derived from absence in two searches, not from a confirmed empty register]
Territorial Rights
Split three ways. Immutep retains North America, Europe and Japan - which includes both launch markets. Dr. Reddy's Laboratories SA holds an exclusive licence everywhere outside North America, Europe, Japan and Greater China (US$20M upfront, up to US$349.5M milestones, double-digit royalties); EOC Pharma holds Greater China. Immutep keeps global manufacturing rights and supplies its partners. Note the direction of travel: Immutep repaid US$10M of the Dr. Reddy's upfront in June 2026 following the TACTI-004 discontinuation. [VERIFIED - Immutep / Dr. Reddy's release 2025-12-08]; the repayment [WEB ESTIMATE - Q4 FY26 reporting coverage via web search, 2026-08-19]
Read
2026-10-17

Valuation

Peak-sales scenarios and capital needs

Scope
The build below is for the SOFT TISSUE SARCOMA indication only - the indication this catalyst is about - and is conditional on an approval that is not currently funded to be pursued. It excludes every other efti indication, all Dr. Reddy's and EOC Pharma territories, and any value from IMP761.
Eligible Patients Per Year
Roughly 5,000-7,000 across the US and EU5. Build: about 13,000 new soft tissue sarcomas a year in the US, of which roughly 60% are localised, of which perhaps half arise in the extremities or trunk, of which perhaps half to 60% are grade 2-3 and larger than 5 cm - around 2,000-2,300 US patients a year. Europe carries roughly 23,400 soft tissue sarcomas a year across the EU27; the same fractions give roughly 3,500-4,000 in the EU5. US incidence and the 60% localised share, and the EU totals, are [WEB ESTIMATE - SEER-derived and RARECARE epidemiology via web search, 2026-08-19]; the extremity, grade and size fractions are [UNVERIFIED - modelled, from the trial's own eligibility criteria applied to the epidemiology].
Peak Sales Low Musd
18
Peak Sales Base Musd
75
Peak Sales High Musd
192
Peak Sales Build
Low
6,000 eligible US + EU5 patients/year x 10% peak penetration x US$30,000 per neoadjuvant course = ~US$18M. 10% assumes use only at high-volume sarcoma centres already giving neoadjuvant pembrolizumab.
Base
6,000 x 25% x US$50,000 = ~US$75M. 25% assumes adoption at the sarcoma referral centres treating most of this population but not universal use. US$50,000 for a nine-week, five-dose course sits well below a year of pembrolizumab at US list and above a generic-supported regimen, on the argument that it is priced as an add-on to an already-expensive backbone.
High
6,000 x 40% x US$80,000 = ~US$192M. 40% assumes guideline inclusion alongside pembrolizumab.
Price Caveat
Every price above is [UNVERIFIED - modelled] and has NO external basis, because eftilagimod alfa has never been priced in any market.
Two Things At Once
These are small numbers by oncology standards: an orphan neoadjuvant indication is a fraction of what first-line lung cancer would have been. They are also large against what the equity costs: on 2026-10-17 the market capitalisation is about US$23.6M and the enterprise value is negative (about -US$19.1M; company.md C.4), so the market assigns the whole pipeline less than nothing. Which fact dominates depends on whether a registrational trial is funded, which on 2026-10-17 it is not. (Updated from the 2026-08-19 wording, which cited an enterprise value of about US$9.6M.)
Third Party Figure Rejected
The dedicated peak-sales web search returned no peak-sales figure for eftilagimod alfa in any indication. It did return a 'consensus price target is AU$1.30' figure - roughly 23x the current ordinary-share price - which is REJECTED under 01-rules.md rule 6 as a stale pre-discontinuation number no source dated or stood behind. The current dated analyst figures are recorded in market_timing instead.
Enpv
Not computed. A.6 now bounds the probability of approval (2-10%), but the registrational trial's cost and design, and who would bear it, are undisclosed.
Capital To Next Decision Point
Essentially nil. The trial is run and funded by the Warsaw institution, enrolment is closed, and the October catalyst is an ePoster.
Capital To Approval
A randomised registrational neoadjuvant sarcoma trial is a multi-year, multi-site undertaking; SARC032 needed 20 institutions and six years (2017-11 to 2023-11) to randomise 143 patients. The company targets a start in 2H CY2027 'subject to ... partnering and resources' (6-K 2026-09-11); no cost or funding plan is disclosed.
Launch Capability
Must partner, without qualification. Immutep has no commercial infrastructure of any kind and has never sold a product.
Peak Sales Usd
Low
18,000,000
Base
75,000,000
High
192,000,000
Launch Year Assumed
2,033
Economic Share
Value
1
Basis
US and EU5, the modelled markets, are fully retained by Immutep; no launch partner exists.
Rejected Inputs
US$79M a year by 2038 for efti across all indications (GlobalData via Pharmaceutical Technology): not indication-specific; not used., AU$1.30 consensus target (2026-08-19 sweep): stale pre-failure figure, rejected under 01-rules.md rule 6., Jefferies A$0.04 target used as an anchor on 2026-08-19: an analyst target is not an admissible anchor from 6.2.0 (01-rules.md rule 30); not used.

Market timing

Positioning into this event

Plain Takeaway
A secondary quality-of-life abstract publishes in two days, on a trial whose real result came out seventeen months ago. The stock trades at US$3.20, 27% below its cash floor of US$4.37, after falling 60% since the last lock; no readable options; about US$86,000 a day on Nasdaq; a quarterly report due inside the window.
Months To Catalyst
0.1
Months To Catalyst Note
Two days, 2026-10-17 to readout.window.earliest 2026-10-19; DAY precision.
Expected Move
Bracket roughly +/-5% to +/-25%; the chain is unreadable (company.md C.6). Class averages Phase 2 +12%/-16%, oncology +9%/-9%, single-arm amplitude 7% [WEB ESTIMATE - IQVIA 2024], outranked by the ticker's own +1.81% median and its thin liquidity.
Nearest Comparable Past Reaction
2025-10-20, -1.68%: the same trial's full primary data at ESMO 2025 (company.md C.7).
Materiality
Meaningful at the programme level, immaterial at the event level (company.md C.2).
Spot
Price
$3.20
As Of
2026-10-16
Kind
settled close
Basis
1 ADS = 200 ordinary shares
Superseded Spot Conversion
US$0.40 on 2026-08-19 on the 1 ADS = 10 basis = US$8.00 on today's basis; today's spot is 60% lower
Listing Deadline
Resolved: Nasdaq confirmed compliance on 2026-10-12 after the 2026-09-28 ratio change.

Chemistry (ChEMBL)

Compound identity and properties

State
CALLED
Record
CHEMBL4594557, pref_name EFTILAGIMOD ALFA, max_phase 2, synonyms Eftilagimod alfa / Immufact / IMP321, USAN stem 'ef-; -imod' (Fc fusion protein; immunomodulators), first_approval null, orphan flag 0.
What It Establishes
Molecule identity, and that ChEMBL knows of no approval anywhere.
What It Does Not
No selectivity or off-target data at all: structure_type is NONE, molecule_properties is null, and there is no SMILES string, because ChEMBL's bioactivity data are built around small molecules and this is a recombinant fusion protein. The same limitation 02-connectors.md records for an antibody, and the cost is small for the same reason. Note also that ChEMBL's orphan flag reads 0 against an FDA Orphan Drug Designation granted 2026-04-15 - the field is stale, not a contradiction of the designation.
Read
2026-10-17

Readout

Window
Earliest
2026-10-19
Likeliest
2026-10-19
Latest
2026-10-19
Precision
DAY
Confidence
HIGH
Basis
One moment discloses the numbers: Immutep stated on 2026-07-24 that the full abstract publishes on the ESMO Congress 2026 website on Monday 19 October 2026, online at 00:05 CEST (18:05 on Sunday 18 October in New York, so the first US session able to react is 2026-10-19). The ePoster 3788eP shown during the congress on 23-27 October carries the same content and is not a second readout. Precision is DAY because the company names the day; confidence is HIGH because the trial is complete, the abstract is accepted and the date is a publisher's calendar. Corrected after the first lock and kept from the 2026-08-19 version: the window was first written with latest 2026-10-27, which counted the congress tail twice; it was narrowed rather than relabelled.
Sources
Source 1
Kind
bpiq
Value
2026-10-19
Text
October 19, 2026
As Of
2026-10-17
Tag
VERIFIED - BPIQ fetch_company_drugs 2026-10-17
Source 2
Kind
ctgov
Value
2025-04-30
Field
primary_completion_date
Nct
NCT06128863
As Of
2026-10-17
Tag
VERIFIED - CT.gov get_trial_details NCT06128863, 2026-10-17
Source 3
Kind
company
Value
2026-10-19
As Of
2026-07-24
Url
https://www.immutep.com/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026/
Tag
VERIFIED - Immutep release 2026-07-24
Source 4
Kind
congress
Value
2026-10-23/2026-10-27
Name
ESMO Congress 2026, IFEMA Madrid
As Of
2026-10-17
Tag
VERIFIED - data/congresses.json, confirmed against esmo.org
Source 5
Kind
modelled
Value
2025-06-30/2025-08-31
Method
CT.gov primary_completion_date 2025-04-30 plus the default two-to-four-month lag (01-rules.md rule 34; data/benchmarks/readout-lag.json holds no matching entry).
As Of
2026-10-17
Tag
UNVERIFIED - modelled, default lag
Disagreement
CONSISTENT
Disagreement Note
BPIQ's 2026-10-19 and the congress's 23-27 October are two moments of one event, both stated in the company's release of 2026-07-24.
Slips
Count
0
Sequence
Sequence 1
As Of
2026-07-24
Text
The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026
Sequence 2
As Of
2026-07-30
Text
EFTISARC-NEO HRQoL ESMO 2026 presentation reiterated; disease-free survival follow-up continues

Attribution

Status
CONTAMINATED
Conflicts
Conflict 1
Bpiq Drug Id
18,203
Label
IMP761 (LAG-3 agonist)
Date
2026-12-31
Analysed
No
Gap Days
0
Confirmed
Yes

Asset Evaluation

Mode
A
Search Date
2026-10-17
Modality
other
Therapeutic Area
oncology
Orphan
Us
Yes
Scores
Score 1
Section
A.2
Criterion
Target validation
Score
3
Tag
VERIFIED - Open Targets 2026-10-17 (no genetic association); Immutep 2026-03-13 (TACTI-004 futility)
Score 2
Section
A.2
Criterion
Mechanism and target engagement
Score
6
Tag
VERIFIED - PubMed (Atkinson 2020, Forster 2024); Immutep 2026-07-13
Score 3
Section
A.2
Criterion
Translational biomarkers
Score
4
Tag
VERIFIED - Immutep releases 2026-05-28 and 2025-11-13
Score 4
Section
A.2
Criterion
Clinical effect against standard of care
Score
4
Tag
VERIFIED - FY26 annual report; Mowery et al., Lancet 2024
Score 5
Section
A.2
Criterion
Consistency and replication
Score
4
Tag
VERIFIED - CT.gov
Score 6
Section
A.2
Criterion
Therapeutic window and safety
Score
8
Tag
VERIFIED - PubMed; Immutep 2025-11-13
Score 7
Section
A.2
Criterion
Data transparency and expert view
Score
4
Tag
UNVERIFIED - expert view score
Score 8
Section
A.5
Criterion
Recruitment feasibility
Score
3
Tag
VERIFIED - CT.gov NCT06128863; Lancet 2024
Score 9
Section
A.5
Criterion
Endpoint acceptance
Score
3
Tag
VERIFIED - CT.gov NCT06128863
Score 10
Section
A.5
Criterion
Design robustness
Score
2
Tag
VERIFIED - CT.gov NCT06128863
Score 11
Section
A.5
Criterion
Execution track record
Score
6
Tag
VERIFIED - Immutep filings; company.md C.1a
Score 12
Section
M.6
Criterion
Process robustness and CQAs
Score
2
Tag
VERIFIED - Immutep 6-K 2026-09-11
Score 13
Section
M.6
Criterion
Regulatory CMC record
Score
6
Tag
UNVERIFIED - absence of a record; never filed or inspected
Score 14
Section
M.6
Criterion
Capacity and supply
Score
4
Tag
VERIFIED - FY26 annual report note 18
Score 15
Section
M.6
Criterion
Cost of goods
Score
6
Tag
UNVERIFIED - no COGS disclosed
Score 16
Section
B.1
Criterion
Mechanism differentiation
Score
8
Tag
VERIFIED - PubMed (Giri 2025)
Score 17
Section
B.1
Criterion
Timing against competitors
Score
2
Tag
VERIFIED - Lancet 2024; Immutep 6-K 2026-09-11
Score 18
Section
B.1
Criterion
Clinical data against competitors
Score
5
Tag
UNVERIFIED - indirect cross-trial comparison
Score 19
Section
B.1
Criterion
IP and exclusivity
Score
5
Tag
VERIFIED - FY26 annual report; Immutep 2026-04-15
Score 20
Section
B.3
Criterion
Comparator alignment
Score
2
Tag
VERIFIED - CT.gov NCT06128863
Score 21
Section
B.3
Criterion
Endpoints and certainty
Score
2
Tag
VERIFIED - CT.gov NCT06128863
Score 22
Section
B.3
Criterion
Supplementary evidence plan
Score
4
Tag
VERIFIED - Immutep 2026-07-24
Score 23
Section
B.3
Criterion
Value for money at the target price
Score
4
Tag
UNVERIFIED - no price and no comparative effect
Score 24
Section
B.3
Criterion
Payer precedent
Score
4
Tag
VERIFIED - G-BA olaratumab decisions; NICE TA465, TA185
Stage Gate
Stage Gate 1
Id
T1
Gates
phase2, phase3
Rating
amber
Confidence
M
Stage Gate 2
Id
T2
Gates
phase2, phase3
Rating
green
Confidence
M
Stage Gate 3
Id
T3
Gates
phase2, phase3, filing
Rating
green
Confidence
H
Stage Gate 4
Id
D1
Gates
phase2, phase3, filing
Rating
amber
Confidence
M
Stage Gate 5
Id
D2
Gates
phase2, phase3, filing
Rating
green
Confidence
H
Stage Gate 6
Id
D3
Gates
phase2, phase3, filing
Rating
red
Confidence
M
Stage Gate 7
Id
D4
Gates
phase3, filing
Rating
amber
Confidence
L
Stage Gate 8
Id
P1
Gates
phase2, phase3, filing
Rating
red
Confidence
M
Stage Gate 9
Id
P2
Gates
phase2, phase3, filing
Rating
green
Confidence
M
Stage Gate 10
Id
P3
Gates
phase2, phase3
Rating
amber
Confidence
L
Stage Gate 11
Id
P4
Gates
phase3, filing
Rating
amber
Confidence
M
Stage Gate 12
Id
R1
Gates
phase3, filing
Rating
amber
Confidence
M
Stage Gate 13
Id
R2
Gates
phase3, filing
Rating
amber
Confidence
L
Domains
Scientific Rationale
Score
4.7
Weight
15
Method
mean
Basis
Mean of the seven A.2 criterion scores (3, 6, 4, 4, 4, 8, 4).
Clinical Data Design
Score
4
Weight
20
Method
direct
Basis
Direct score citing A.3: one single-arm trial of 38 evaluable patients met a surrogate endpoint (P4 amber); D3 (product comparability) and P1 (no agreed design or endpoint) are red; no comparison against pembrolizumab plus radiotherapy exists (R2 amber). Confidence Medium.
Regulatory Pathway
Score
4
Weight
10
Method
direct
Basis
Direct score citing A.4: FDA Orphan Drug Designation held (2026-04-15), but no agreed registrational design or endpoint, no approval precedent for hyalinization, and an open manufacturing comparability question as the central review risk. Confidence Medium.
Operations Cmc
Score
4
Weight
10
Method
mean
Basis
Mean of the A.5 mean (3.5: 3, 3, 2, 6) and the M.6 CMC score (4.5: 2, 6, 4, 6).
Competitive Position
Score
5
Weight
15
Method
mean
Basis
Mean of the four B.1 metric scores (8, 2, 5, 5).
Market Access
Score
3.2
Weight
15
Method
mean
Basis
The B.3 Market Access Score: mean of the five criteria (2, 2, 4, 4, 4).
Risk Profile
Score
3
Weight
15
Method
direct
Basis
Direct score citing C (10 = low risk): science and clinical, CMC and supply, and execution and financing all sit at high likelihood and high impact; only non-clinical risk is low. Confidence Medium.
Weighted Total
4
Cmc Score
4.5
Market Access Score
3.2
Pos
Base Rate
Value Pct
24.6%
Phase
phase2
Area
oncology
Modality
other
Transition
next_phase
Adjustments
Adjustment 1
Factor
Human genetic support for the target
Direction
down
Evidence
Open Targets finds no genetic association between LAG3 and soft tissue sarcoma (overall score 0.104 from literature and clinical evidence only).
Tag
VERIFIED - Open Targets, 2026-10-17
Adjustment 2
Factor
Rare disease or orphan designation
Direction
up
Evidence
FDA Orphan Drug Designation in soft tissue sarcoma, 2026-04-15.
Tag
VERIFIED - Immutep release 2026-04-15
Adjustment 3
Factor
Randomised Phase 2 with a meaningful effect
Direction
down
Evidence
EFTISARC-NEO is single-arm; the comparison is historical.
Tag
VERIFIED - CT.gov NCT06128863
Adjustment 4
Factor
Prior failures in the program
Direction
down
Evidence
TACTI-004 stopped for futility; AIPAC missed progression-free survival; AIPAC-003 terminated.
Tag
VERIFIED - Immutep 2026-03-13; PubMed; CT.gov
Adjustment 5
Factor
Primary endpoint met by a wide margin
Direction
up
Evidence
Median 51.5% hyalinization against a pre-specified 35% target.
Tag
VERIFIED - FY26 annual report
Adjustment 6
Factor
No designed or funded next trial
Direction
down
Evidence
Registration-directed trial start targeted for 2H CY2027, subject to design, regulators, manufacturing, partnering and resources.
Tag
VERIFIED - Immutep 6-K 2026-09-11
Adjustment 7
Factor
Manufacturing comparability open
Direction
down
Evidence
Root cause analysis found N-glycan differences between 2,000 L and 200 L product; a new 200 L run is contracted.
Tag
VERIFIED - Immutep 6-K 2026-09-11
Next Phase
Low
10
Base
20
High
35
Approval
Low
2
Base
5
High
10
Asset Verdict
Verdict
monitor
Reason
A genuinely novel mechanism with a clean safety record and a met surrogate endpoint in an orphan indication. The asset cannot be valued until a randomised trial against pembrolizumab plus radiotherapy is designed and funded, and until the 200 L versus 2,000 L manufacturing question is closed. Confidence Medium.

Kol

As Of
2026-10-17
Investigators
Investigator 1
Name
Pawel Teterycz
Role
First author of the ESMO 2026 EFTISARC-NEO HRQoL abstract, per the company
Affiliation
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Nct
NCT06128863
Conflicts
Conflict 1
Party
sponsor
Kind
institutional - his department sponsors a trial for which Immutep S.A.S. is collaborator and drug supplier
Disclosed In
Immutep release 2026-07-24 naming him as first author
As Of
2026-07-24
Conflicts Checked
PubMed search_articles 'Teterycz P[Author] AND sarcoma' (56 hits) and get_article_metadata on three, 2026-10-17 - affiliations only, no conflict-of-interest field; absence of a disclosure is not evidence of no conflict, CT.gov search_investigators investigator_name 'Teterycz', 2026-10-17 - no trials returned, No NIH RePORTER search - outside its scope
Tag
VERIFIED - Immutep release 2026-07-24, for the authorship
Investigator 2
Name
Pawel Teterycz
Role
First author of the ESMO 2026 EFTISARC-NEO HRQoL abstract, per the company
Affiliation
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Nct
NCT06128863
Conflicts
Conflict 1
Party
sponsor
Kind
institutional - his department sponsors a trial for which Immutep S.A.S. is collaborator and drug supplier
Disclosed In
Immutep release 2026-07-24 naming him as first author
As Of
2026-07-24
Conflicts Checked
PubMed search_articles 'Teterycz P[Author] AND sarcoma' (56 hits) and get_article_metadata on three, 2026-10-17 - affiliations only, no conflict-of-interest field; absence of a disclosure is not evidence of no conflict, CT.gov search_investigators investigator_name 'Teterycz', 2026-10-17 - no trials returned, No NIH RePORTER search - outside its scope, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field
Tag
VERIFIED - Immutep release 2026-07-24, for the authorship
Investigator 3
Name
Pawel Teterycz
Role
First author of the ESMO 2026 EFTISARC-NEO HRQoL abstract, per the company
Affiliation
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Nct
NCT06128863
Conflicts
Conflict 1
Party
sponsor
Kind
institutional - his department sponsors a trial for which Immutep S.A.S. is collaborator and drug supplier
Disclosed In
Immutep release 2026-07-24 naming him as first author
As Of
2026-07-24
Conflicts Checked
PubMed search_articles 'Teterycz P[Author] AND sarcoma' (56 hits) and get_article_metadata on three, 2026-10-17 - affiliations only, no conflict-of-interest field; absence of a disclosure is not evidence of no conflict, CT.gov search_investigators investigator_name 'Teterycz', 2026-10-17 - no trials returned, No NIH RePORTER search - outside its scope, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field
Tag
VERIFIED - Immutep release 2026-07-24, for the authorship
Investigator 4
Name
Piotr Rutkowski
Role
Head, Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw - the trial's sponsoring department. NOT confirmed as an investigator on this trial by the registry.
Affiliation
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Nct
NCT06128863
Conflicts
Conflict 1
Party
sponsor
Kind
institutional - his department is the sponsor of a trial for which Immutep S.A.S. is the named collaborator and drug supplier
Disclosed In
author affiliation, Wisniewska et al., Autoimmunity Reviews 2026, DOI 10.1016/j.autrev.2026.103992 (PMID 41587647)
As Of
2026-01-24
Conflicts Checked
PubMed get_article_metadata PMID 41587647, 2026-08-19 - the returned record carries full affiliations but no conflict-of-interest statement field; per 02-connectors.md the absence of a disclosure is not evidence of no conflict, CT.gov search_investigators, institution 'Maria Sklodowska-Curie', 2026-08-19 - 51 investigators returned across 18 sarcoma trials, none of them on NCT06128863, No NIH RePORTER funding search was run - a Polish investigator is outside that register's scope, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field
Tag
UNVERIFIED - inferred from institutional authorship, not from the trial record
Investigator 5
Name
Pawel Sobczuk
Role
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie NRIO, Warsaw, and Sarcoma Translational Research Group, Vall d'Hebron Institute of Oncology, Barcelona. Corresponding author of the 2026 LAG-3 review. NOT confirmed as an investigator on this trial by the registry.
Affiliation
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Vall d'Hebron Institute of Oncology, Barcelona, Spain
Nct
NCT06128863
Conflicts
Conflict 1
Party
sponsor
Kind
institutional - his department is the sponsor of a trial for which Immutep S.A.S. is the named collaborator and drug supplier
Disclosed In
author affiliation, Wisniewska et al., Autoimmunity Reviews 2026, DOI 10.1016/j.autrev.2026.103992 (PMID 41587647)
As Of
2026-01-24
Conflicts Checked
PubMed get_article_metadata PMID 41587647, 2026-08-19 - affiliations returned, no conflict-of-interest statement field in the record, CT.gov search_investigators, institution 'Maria Sklodowska-Curie', 2026-08-19 - not returned on NCT06128863, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field, PubMed PMID 41587647 re-read 2026-10-17 - still no conflict-of-interest field
Tag
UNVERIFIED - inferred from institutional authorship, not from the trial record
Independent Voices
Independent Voice 1
Name
Vinay K. Giri, David F. McDermott and Jacob Zaemes
Affiliation
Division of Medical Oncology, Harvard Medical School / Beth Israel Deaconess Medical Center, Boston, Massachusetts
View
In a review of LAG-3 targeting across solid malignancies that names eftilagimod among the agents surveyed: 'To date, the most significant demonstration of efficacy in targeting LAG-3 has been the use of relatlimab with the PD-1 inhibitor nivolumab in the treatment of advanced melanoma.' Read plainly, that places eftilagimod alfa BELOW the LAG-3 blocking antibody on demonstrated efficacy. It says nothing at all about sarcoma or about quality of life.
As Of
2025-05-15
Conflicts Checked
PubMed get_article_metadata PMID 40344213, 2026-08-19 - the returned record carries affiliations but no conflict-of-interest statement field, so no relationship with Immutep or with a competitor was found and none can be certified absent, No NIH RePORTER funding search was run, PubMed PMID 40344213 re-read 2026-10-17 - no conflict-of-interest field, PubMed PMID 40344213 re-read 2026-10-17 - no conflict-of-interest field, PubMed PMID 40344213 re-read 2026-10-17 - no conflict-of-interest field
Tag
VERIFIED - PubMed get_article_metadata, 2026-10-17
Judgement
Endpoint Supported
UNKNOWN
Basis
No independent voice has commented on either endpoint that matters here, hyalinization or quality of life. The one voice found comments on the LAG-3 class and places efti behind relatlimab on demonstrated efficacy; the trial has no publication to attract commentary.
Tag
UNVERIFIED - judgement

Risk flags

  • Backbone confound: the effect may belong to pembrolizumab plus radiotherapy.
  • Manufacturing comparability between 2,000 L and 200 L product (potential near-veto until closed).
  • Registrational trial unfunded; start targeted 2H CY2027 against runway well into H1 CY2028.
  • Unregistered catalyst endpoint; undisclosed instrument.
  • ADS trades 27% below the cash floor; any raise would be heavily dilutive.

Full analysis

The full written analysis. Each claim is tagged with the kind of evidence behind it.

IMMP / efti-pembrolizumab-soft-tissue-sarcoma — Eftilagimod alfa with pembrolizumab and radiotherapy, given before surgery for soft tissue sarcoma

Program analysis · bpiq_drug_id 17452 · Mode A (prospective) · prepared 2026-10 · search date 2026-10-17 · USD · framework v6.2.0 · Coverage: CLEARED

Asset. Eftilagimod alfa (INN) · IMP321, “efti” · no brand name · Immutep Limited, through Immutep S.A.S.; the trial is run by the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw. Immutep keeps North America, Europe and Japan. Dr. Reddy’s Laboratories holds the other territories except Greater China, which EOC Pharma holds [1] Biology and modality. MHC class II on antigen-presenting cells · a soluble LAG-3 fusion protein that switches those cells on · modality other (an Fc fusion protein, not an antibody) [2] Indication. Soft tissue sarcoma · given before surgery (neoadjuvant), resectable, non-metastatic, grade 2–3, limbs, girdles or superficial trunk · no biomarker subgroup · therapeutic area oncology · orphan status US yes, EU unknown [3] [4] Status. Phase 2 · EFTISARC-NEO, NCT06128863, primary endpoint met in 2025 · FDA Orphan Drug Designation (2026-04-15) · no approval anywhere [3] [4] Launch markets. United States and the EU5 (Germany, France, Italy, Spain, United Kingdom), the markets Immutep keeps. Japan is also kept but is not modelled. No launch plan is announced [1] [5]

Company context, financials, ownership, options and the full pipeline: ../company.md.

How to read this. Written for a curious reader with little or no background in science, medicine, the drug industry or finance. Terms specific to this program are explained in the Glossary below. General terms are explained once in the glossary. All money figures are in US dollars (USD). Every fact carries one of three tags. [VERIFIED — source] means a primary source confirmed it, and the source is named. [UNVERIFIED] means it could not be confirmed. [WEB ESTIMATE — source, date] means it is a third-party figure or a labelled model.

Confidence legend. Every conclusion carries a confidence beside it (01-rules.md rule 1). A conclusion is a judgement drawn from several facts: a score, a rating, an answer to a Go / No-Go question, or a verdict. High means the evidence under it is primary, consistent and recent. Medium means the evidence is partial, indirect or mixed. Low means the judgement rests mostly on inference or on sources that could not be verified.

Sources. Every source is cited as a number in square brackets, [n]. The numbers run through the document in the order of first use. The Sources list at the end gives one link per number (01-rules.md rule 20). “No public record as of 2026-10-17” means a search on that date found nothing.

One unit change to know before reading any price. On 2026-09-28 the American Depositary Share (ADS) changed from 10 ordinary shares to 200 ordinary shares. One new ADS replaced twenty old ones. Every price in this document is on the new basis. The superseded 2026-08-19 record’s spot of US$0.40 equals US$8.00 on the new basis. See ../company.md C.4.

Glossary

TermPlain-language meaning
Eftilagimod alfa (efti; earlier IMP321)The drug. A manufactured, soluble copy of the outer part of the human immune protein LAG-3, joined to an antibody tail, injected under the skin. It does not block anything: it switches immune cells on.
LAG-3 (lymphocyte activation gene-3)A protein on activated T cells that acts as a brake there. As a free-floating manufactured protein it does something else: it binds antigen-presenting cells and wakes them up.
MHC class IIA molecule on antigen-presenting cells that holds up protein fragments for T cells to inspect. Efti attaches to it.
Antigen-presenting cell (APC)An immune cell, such as a dendritic cell or a monocyte, that shows T cells what a threat looks like.
Soft tissue sarcoma (STS)A rare cancer that starts in muscle, fat, nerve or connective tissue. It is most often found in an arm, a leg or the trunk.
NeoadjuvantGiven before the operation that removes the tumour. Adjuvant means after surgery.
ResectableThe tumour can be removed by surgery.
FNCLCC gradeThe French three-level grading of sarcoma aggressiveness, from 1 (least) to 3 (most). This trial took grades 2 and 3.
Hyalinization / fibrosisWhat a treated tumour turns into when it dies in place: glassy scar tissue. A pathologist measures what share of the removed tumour has turned to scar.
Pathologic responseJudging treatment by looking at the removed tumour under a microscope.
Health-related quality of life (HRQoL)What patients report about how they feel and function, on a standard questionnaire. This is what the October 2026 catalyst reports.
EORTC QLQ-C30The most widely used cancer quality-of-life questionnaire in Europe. Its global health status score runs 0–100, and higher is better. A change of about 10 points is conventionally treated as one patients notice.
ePosterAn electronic poster at a medical congress. The lowest-visibility format: no talk and no discussant.
EFTISARC-NEOThe trial: a 40-patient, single-arm, single-site Phase 2 study in Warsaw, testing efti added to pembrolizumab and radiotherapy before surgery.
SARC032The competitor precedent: a randomised trial of pembrolizumab added to radiotherapy before surgery in the same disease. It met its primary endpoint.
200 L and 2,000 L scaleThe size of the steel tanks the drug is grown in. Efti from the two sizes was found in 2026 to differ slightly in its sugar chains (N-glycans).
N-glycanA sugar chain attached to a protein during manufacture. Small differences can change how a protein behaves in the body.

Executive scorecard

Asset snapshot

Asset snapshot
Asset and sponsorEftilagimod alfa (IMP321), Immutep Limited. Trial sponsor: Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, with Immutep S.A.S. as collaborator. Immutep keeps North America, Europe and Japan; Dr. Reddy’s holds most other territories; EOC Pharma holds Greater China [1] [3]
Modality and mechanismother: an Fc fusion protein. A soluble LAG-3 protein that binds MHC class II on antigen-presenting cells and switches them on. Key design feature: it is an agonist (it activates), unlike every other LAG-3 drug, which blocks [2]
Targeted indications (Mode A) or approved indications (Mode B)Resectable, non-metastatic, grade 2–3 soft tissue sarcoma of the limbs, girdles or superficial trunk, before surgery, with radiotherapy and pembrolizumab. No biomarker selection [3]
Stage and modePhase 2 (primary endpoint met 2025) · Mode A
Next catalysts (Mode A) or commercial status (Mode B)EFTISARC-NEO health-related quality-of-life abstract, online 2026-10-19 at 00:05 CEST; ePoster 3788eP at ESMO Congress 2026, Madrid, 23–27 October. Readout window 2026-10-19 (DAY, HIGH) [6]
Asset verdictSee the asset verdict below

Domain scores

The weights are v2.2’s defaults [UNVERIFIED — default weight]. Every derived figure below was computed by scorecard in lib/scorecard.mjs.

DomainSectionsWeightScore (1–10)RatingKey driver (one line)
Scientific rationaleA.1–A.215%4.7amberA clean safety record and a reproducible immune signal, against no human genetic support and one failed randomised test of the hypothesis
Clinical data and designA.320%4.0amberOne 38-patient single-arm trial met a surrogate endpoint; no comparison against today’s pembrolizumab-plus-radiotherapy regimen
Regulatory pathwayA.410%4.0amberOrphan Drug Designation held, but no agreed registrational endpoint or design
Operations and CMCA.5, M10%4.0amberSingle-site uncontrolled design, and a 2026 finding that commercial-scale product differs from the product that worked
Competitive positionB.115%5.0amberThe only MHC class II agonist in the clinic, but years behind an add-on regimen that already has randomised data
Market accessB.2–B.315%3.2redSingle-arm surrogate data, no comparator and no payer precedent for an add-on in this setting
Risk profile (10 = low risk)C15%3.0redUnfunded registrational trial, a manufacturing comparability question and a backbone that works without the drug
Weighted total100%4.0amber

Key metrics

Key metricLowBaseHighSource or assumption [n]
Probability of success to the next phase (A.6)10%20%35%A.6; base rate 24.6% [WEB ESTIMATE — BIO/Informa/QLS 2021] [7]
Probability of success to approval (A.6)2%5%10%A.6; base rate 10.8% [WEB ESTIMATE — BIO/Informa/QLS 2021] [7]
Peak sales, USD per year (B.4a)US$18MUS$75MUS$192MB.4a, STS only, US and EU5, modelled [UNVERIFIED — modelled]
eNPV, USD (B.4b)not computednot computednot computedB.4b: the cost and design of the registrational trial are undisclosed
Market Access Score (B.3)3.2B.3, from lib/scorecard.mjs

Top-3 box

  • Top-3 value drivers. 1. The only MHC class II agonist in clinical development, with no grade 3 or higher toxicity attributed to it in this trial [3] [8]. 2. A met primary endpoint by a wide margin: median 51.5% hyalinization against a pre-specified 35% target [5]. 3. Orphan Drug Designation in the US, and since 2026-09-11 one of only two indications the company intends to take into registration-directed trials [4] [9].
  • Top-3 risks, each with its mitigation. 1. The effect cannot be separated from the pembrolizumab-plus-radiotherapy backbone, which works on its own [10]. Mitigation: a randomised trial against that backbone, which is not yet designed or funded. 2. Manufacturing: the root cause analysis found that efti made at 2,000 L scale differs in its sugar chains from the 200 L product used in earlier positive trials [9]. Mitigation: a new 200 L run is contracted. 3. Financing: the next trials are targeted for 2H CY2027, “subject to … partnering and resources” [9]. Mitigation: about A$61M of cash net of debt-like items at 2026-06-30, and a licensing partner consulted on the plan.
  • Evidence gaps, and whether each is still fixable at this stage. 1. No randomised comparison against pembrolizumab plus radiotherapy: fixable, only by the next trial. 2. No disease-free survival data yet: fixable, follow-up runs to 2027-04-30 [3]. 3. No peer-reviewed publication of EFTISARC-NEO seventeen months after the primary endpoint: fixable at any time.

Asset verdict

Asset verdict: Monitor. A genuinely novel mechanism with a clean safety record and a met surrogate endpoint in an orphan indication. The asset cannot be valued until a randomised trial against the current add-on regimen is designed and funded, and until the manufacturing question is closed. · confidence Medium

Visual 1: the seven domain scores

Seven domain scores

Source(s): the domain table above, computed by lib/scorecard.mjs from the scores in A.2, A.3, A.4, A.5, M.6, B.1, B.3 and C [3] [5] [9] [10]

Visual 2: milestones

Milestones

Source(s): CT.gov NCT06128863 [3]; Immutep releases and filings [1] [4] [5] [6] [9] [11] [12] [13]

Visual 2b: clinical study timeline

Clinical study timeline

Source(s): dates and n from CT.gov [3] [14] [15] [16] [17] [18] [19] [20]; the efti plus avelumab stratum’s end date is its final-data presentation at ASCO 2021, from the BPIQ note on row 16013, approximated to the month [21]; the next trial’s bar is the company’s 2H CY2027 target [9]. Date basis: registry dates as of 2026-10-17. TACTI-004 is shown to its discontinuation, not to its registry date.

Studies supporting key target-profile claims.

  1. EFTISARC-NEO (NCT06128863): the efficacy, safety and regimen rows of A.1 [3] [5] [8].
  2. SU2C-SARC032 (NCT03092323): the standard-of-care and competitor column of A.1 [10].
  3. AIPAC (NCT02614833): the precedent that efti sustained quality of life in a randomised trial [22].
  4. TACTI-mel and the INSIGHT efti plus avelumab stratum: the 30 mg dose [2] [21].
  5. TACTI-004 (NCT06726265): the failed randomised test that sets the scientific risk [11].

Rationale for the clinical development plan. The neoadjuvant setting lets investigators see the drug’s effect in the removed tumour within weeks. EFTISARC-NEO was the cheap, fast first test of that idea. A registrational trial would have to compare efti plus pembrolizumab plus radiotherapy against pembrolizumab plus radiotherapy, with disease-free survival as the endpoint.

Key Go / No-Go to the next decision point. The next decision is the start of a registration-directed trial, targeted for 2H CY2027 [9]. Go criteria: the root cause analysis closes and a comparable product batch exists (D3); an endpoint and design are agreed with the FDA (P1); funding or a partner is secured (B.4c). No-go criteria: the HRQoL data show meaningful harm (this catalyst, 2026-10-19); disease-free survival in EFTISARC-NEO’s 24-month follow-up looks no better than SARC032’s (2027-04-30 or later); the 200 L product fails comparability (date not disclosed).

Clinical pharmacology studies

Study (ID or NCT)TypeDesign and nKey findingLabel or dosing impactSource
TACTI-mel (NCT02676869)Dose escalation (RP2D)Phase 1, open-label, 1, 6 and 30 mg, n=24No dose-limiting toxicity; sustained exposure at 30 mg30 mg carried forward[2] [20]
INSIGHT efti plus avelumab stratumDose escalation (RP2D)Phase 1, 6 or 30 mg, n=12No dose-limiting toxicity; 30 mg set as the recommended Phase 2 dose30 mg every 2 weeks[21]
—Drug–drug interactionnot conductedNo public record as of 2026-10-17None[23]
—QTcnot conductedNo public record as of 2026-10-17None[23]
—Hepatic or renal impairmentnot conductedNo public record as of 2026-10-17None[23]
Pooled analysis of 5 trialsPopulation PK and exposure–responseRetrospective, pharmacodynamic onlyAbsolute lymphocyte count rose on efti; responders lived longer. No PK model publishedNone; an association, not an exposure–response model[24]
AIPAC-003 (NCT05747794)Dose optimisationRandomised dose comparison under FDA Project Optimus30 mg selected as the optimal biological doseConfirms 30 mg[5]
TACTI-mel (NCT02676869)Immunogenicity, food effect, ADME, ethnic bridging (as applicable)Anti-efti antibodies assayedAssayed; the result is not stated in the abstract. Food effect not applicable (injection). No ADME or bridging study foundNone[2]

0. Program-tier coverage — CLEARED

ToolStateNote / verbatim error
CT.gov search_trials + get_trial_details on the pivotal NCTCALLEDsearch_trials on “eftilagimod”: 11 of 11 trials. get_trial_details on NCT06128863: full design, eight outcome measures, other_outcomes null, one site, no investigators listed.
PubMed search_articles + get_article_metadata on every hit (if ≤15)CALLED10 of 10 hits on “eftilagimod”, metadata for all ten, authors complete. The null-authors bug did not fire. No EFTISARC-NEO publication exists. One follow-up query hit Rate limit exceeded and cleared on retry.
Open Targets search_entitiesCALLEDReturned LAG3 (ENSG00000089692), soft tissue sarcoma (MONDO_0018078) and eftilagimod alfa (CHEMBL4594557). A follow-up association query found a LAG3 to soft tissue sarcoma score of 0.104, from literature (0.118) and clinical (0.165) evidence only, with no genetic association. Blocked on 2026-08-19; it answered this time.
ChEMBL compound_searchCALLEDOne record, CHEMBL4594557, max_phase 2, structure_type NONE, no selectivity data (a fusion protein).
web_search ×4: peak sales · competitive · exclusivity + royalty · analystCALLEDPeak sales: no STS-specific figure; one drug-wide figure, rejected (B.4a). Competitive: SARC032 is the only randomised precedent. Exclusivity and royalty: Dr. Reddy’s terms; no patent expiry found. Analyst: no target dated after June 2026; none used.
B.1a competitor efficacy and side-effect search (P4)CALLEDSARC032 per-arm DFS and grade 3+ rates from the Lancet paper; EFTISARC-NEO from Immutep releases.
Orange Book and Purple BookCALLEDWeb search. Efti is unapproved, so no Purple Book entry [25]. Pembrolizumab’s core US patent is expected to expire in 2028 (secondary source).
DailyMed (API)CALLEDTwo pembrolizumab labels (Keytruda, 2026-07-24; Keytruda Qlex, 2026-08-12). No soft tissue sarcoma indication; sarcoma appears only inside the tumour-agnostic data tables.
ICERCALLEDWeb search. No ICER assessment of soft tissue sarcoma or of pembrolizumab in sarcoma found.
CMS Medicare drug price negotiation pageCALLEDPage read; the drug list sits on a sub-page not reached. A secondary source reports that pembrolizumab was not selected for 2028 because of the 2025 orphan-exclusion change.
payer tier EU joint clinical assessmentCALLEDWeb search. No JCA of efti. JCA is mandatory for new oncology medicines filed from January 2025.
payer tier G-BA and IQWiGCALLEDWeb search. Closest analogue: olaratumab in soft tissue sarcoma, 2017 decision, rescinded 2020.
payer tier NICECALLEDWeb search. TA465 (olaratumab, 2017) and TA185 (trabectedin, updated 2021). No neoadjuvant STS appraisal.
payer tier ICERCALLEDAs in the program-tier row.
payer tier ChuikyoCALLEDWeb search. Trabectedin was listed on Japan’s NHI price list on 2015-11-26; no cost-effectiveness record found.
manufacturing tierNot applicablePhase 2; the tier applies from Phase 3 (02-connectors.md § Manufacturing tier).
optional EDGAR full-text search on the drug’s namesNOT CALLEDOptional. The EDGAR filing feed was read at the company tier.
optional Europe PMC searchNOT CALLEDOptional. PubMed returned cleanly.
optional CTIS searchNOT CALLEDOptional. A web search surfaced the EU trial number 2024-515971-37-00 for EFTISARC-NEO.

Company-tier coverage is in ../company.md C.0. It is CLEARED, with the optional Yahoo options cross-check BLOCKED.

What the sweep does not cover. Open Targets answered this time, so the genetics leg of target validation is now a finding instead of a gap: there is no genetic association between LAG3 and soft tissue sarcoma [26]. That matters less than usual, because efti activates a pathway rather than blocking LAG-3. The 2026-08-19 version said the same thing about the cost of the block; that reasoning still holds.


A. Scientific and clinical value

A.1 Target product profile

Target label. Eftilagimod alfa, added to neoadjuvant radiotherapy and pembrolizumab, for adults with resectable, non-metastatic, grade 2–3 soft tissue sarcoma of the limbs, girdles or superficial trunk, with a primary tumour larger than 5 cm or any locally recurrent tumour [3].

AttributeMinimum viableCompetitive (base)High caseStandard of care and key competitors, data [n]Current evidence for efti [n]Rating · confidence
Indication and populationThe EFTISARC-NEO populationThe same, across all histologies that receive neoadjuvant radiotherapyAll resectable high-grade STS before surgeryRadiotherapy then surgery; pembrolizumab added for undifferentiated pleomorphic sarcoma and liposarcoma subtypes, per SARC032 [10]40 patients, one site, mixed histologies (Ewing and rhabdomyosarcoma excluded) [3]amber · Medium
Mechanism and differentiationAdds immune activation without added toxicityShows an effect over pembrolizumab plus radiotherapyThe same, with a response biomarkerPD-1 blockade (pembrolizumab) [10]; LAG-3 blockade (relatlimab) approved in melanoma only [27]The only MHC class II agonist in the clinic; its added effect over the backbone is not isolated [2] [27]amber · Medium
Efficacy (primary and key secondary endpoints)Disease-free survival no worse than pembrolizumab plus radiotherapyDisease-free survival better than pembrolizumab plus radiotherapyOverall survival benefitSARC032: 2-year DFS 67% with pembrolizumab against 52% without; hazard ratio 0.61 (90% CI 0.39–0.96) [10]Median hyalinization 51.5% (n=38) against a 35% target and about 15% historically with radiotherapy alone; no DFS data yet [5] [8]red · Medium
Safety and tolerabilityNo more grade 3+ events than pembrolizumab plus radiotherapyFewerNo more wound complications than radiotherapy aloneSARC032: grade 3+ adverse events 56% with pembrolizumab, 31% without [10]No grade 3+ toxicity attributed to efti or pembrolizumab; the all-cause rate is not disclosed [8]green · Medium
Dose, regimen, route, formulationInjections fit visits the patient already attendsSameFewer dosesPembrolizumab intravenous every 3 weeks, or the subcutaneous Keytruda Qlex form [28]30 mg under the skin every 2 weeks for 9 weeks [3] [21]green · High
Biomarker or companion diagnosticNone neededNone neededA response markerPD-L1 is not used to select sarcoma patients [10]Interferon-gamma, CXCL9 and CXCL10 rose and tracked pathologic response; exploratory [5] [8]amber · Low
Payer value (B.3)Reimbursed as an add-on in an orphan settingPositive HTA with quality-of-life supportPremium pricePembrolizumab is reimbursed for many cancers; no HTA in neoadjuvant STS [28]None. The October HRQoL data are the first evidence on this row (B.3)red · Medium

Stakeholder check

StakeholderWhat they requireDoes the competitive profile meet it? (tagged)Basis [n]
Patient and caregiverBenefit the patient notices; convenienceNot yet shown. Convenience is good: injections at visits already scheduled. A benefit patients notice needs relapse data [UNVERIFIED][3]
RegulatorA favourable balance of benefit against riskNot met. No randomised trial and no agreed endpoint [VERIFIED — CT.gov search_trials, 2026-10-17][3] [9]
Payer and HTA bodyAdded benefit against the comparator, at a price they acceptNot met. The comparator would be pembrolizumab plus radiotherapy, and no comparison exists [VERIFIED — no comparative trial found][10]
PrescriberA fit in treatment guidelines; ease of usePartly. It fits the existing neoadjuvant workflow; it is in no guideline [UNVERIFIED][10]

Value link. The illustrative oncology link is US$150–300M of peak sales per month of overall survival gained [UNVERIFIED — illustrative] (framework/07-benchmarks.md § Rules of thumb). It must be scaled down hard here. The population is about 6,000 patients a year in the modelled markets (B.2), the relevant endpoint is disease-free survival rather than survival, and efti would be a third drug on an existing regimen. No sourced figure exists for this setting.

A.2 Rationale and evidence

What the drug is. Eftilagimod alfa is not an antibody. It is a manufactured, dimeric copy of the outer part of the human LAG-3 protein, joined to an antibody tail so that it stays in the blood. It is given as a 30 mg injection under the skin every two weeks [2] [29].

How it works. On a T cell, LAG-3 is a brake. That is why most companies make antibodies that block it; one, relatlimab, is approved with nivolumab in melanoma [27]. Efti works from the other side. As a free-floating protein it binds MHC class II on antigen-presenting cells and switches those cells on. They mature, show tumour fragments to T cells, and recruit CD4 and CD8 T cells. Blood levels of interferon-gamma and CXCL10 rise [2] [30]. According to PubMed.

Why this combination in this disease. Soft tissue sarcomas are “immune-cold”: they carry few mutations and attract few T cells. Radiotherapy kills tumour cells and releases their contents. Efti switches on the cells that pick that material up. Pembrolizumab then removes the PD-1 brake from the T cells that arrive [3] [31].

How eftilagimod alfa, radiotherapy and pembrolizumab are intended to work together in soft tissue sarcoma, and where the October 2026 catalyst and the 2026 manufacturing finding sit

Source(s): Atkinson et al. 2020 [2]; Forster et al. 2024 [30]; CT.gov NCT06128863 [3]; Immutep strategy release 2026-09-11 for the manufacturing finding [9]

How well the target is validated. The pharmacology repeats across trials. In a pooled analysis of five trials, lymphocyte counts rose on efti and the patients whose counts rose lived longer [24]. That is a retrospective association, not proof. The one properly controlled test, TACTI-004 in lung cancer (756 patients planned, randomised, double-blind), was stopped for futility on 2026-03-13 [11] [15]. In July the company said efti produced “a markedly different immune activation profile” in TACTI-004 than in earlier studies [32]. On 2026-09-11 it gave a reason: efti made at 2,000 L scale, used only in TACTI-004, differs from the 200 L product used in earlier positive trials, for example in N-glycan structure [9]. That is a hypothesis under test, not a proven cause. Human genetics gives no support: Open Targets finds no genetic association between LAG3 and soft tissue sarcoma [26].

The exact scientific step the next readout must prove. None, in efficacy terms. The primary endpoint was met and announced on 2025-05-27, presented at ESMO 2025 on 2025-10-20 and at CTOS 2025 on 2025-11-13 [33] [8] [12]. The October 2026 catalyst is a health-related quality-of-life analysis of the same 40 patients [6]. It must show that adding nine weeks of injections to five weeks of radiotherapy, before major surgery, did not make patients feel meaningfully worse.

The scientific risk, stated honestly.

  1. A single-arm trial cannot separate the drug from the backbone. Every patient also got radiotherapy and pembrolizumab, and pembrolizumab plus radiotherapy works on its own [10].
  2. The endpoint is a surrogate. Hyalinization measures dead tissue, not relapse or survival. The company calls it “an important surrogate marker associated with improved disease-free and overall survival” [5]; no regulator has accepted it in sarcoma.
  3. The catalyst’s own endpoint is not registered. HRQoL is not among the trial’s one primary and seven secondary outcome measures, and other_outcomes is empty [3].
  4. Product comparability. If the 2026 hypothesis is right, the batch scale used in EFTISARC-NEO matters, and it is not disclosed which scale was used [9].

What ChEMBL does and does not establish. One record, CHEMBL4594557, maximum phase 2: the molecule’s identity and that no approval exists. No selectivity data, because ChEMBL’s bioactivity data are built for small molecules [29]. ChEMBL’s orphan flag reads 0 despite the FDA designation; the field is stale.

Evidence quality

CriterionHigh (7–10)Medium (4–6)Low (1–3)Where to checkScoreBasis (tagged) [n] · confidence
Target validationHuman genetic evidence, or a clinical precedent with the same targetStrong preclinical data, indirect human dataPreclinical only, or conflicting dataOpen Targets, GWAS Catalog, literature3Conflicting data: no genetic association [26]; LAG-3 precedent is for blockade, not agonism [27]; the one randomised test failed [11] [VERIFIED — Open Targets, Immutep 2026-03-13] · Medium
Mechanism and target engagementProof of mechanism in people (PK and PD, receptor occupancy)A PD signal with an unclear dose relationNo human PD dataPhase 1 data, publications6Pharmacodynamic rises repeat across trials and 30 mg is dose-selected [2] [30] [5]; but TACTI-004’s product gave a different profile [32] [VERIFIED — PubMed, Immutep 2026-07-13] · Medium
Translational biomarkersA validated PD or selection biomarker with an available assayAn exploratory biomarkerNonePublications, FDA biomarker qualification4Lymphocyte count and interferon-gamma are exploratory and retrospective [24] [8] [VERIFIED — Immutep releases] · Medium
Clinical effect against standard of careRandomised, clinically meaningful effectSingle-arm or small randomised signalNo signal, or a weak oneRegistries, publications, congress data4Single-arm signal against a historical radiotherapy-only figure, not against today’s pembrolizumab regimen [5] [10] [VERIFIED — FY26 annual report; Lancet 2024] · Medium
Consistency and replicationReplicated across trials or subgroupsOne trialInconsistentTrial results4One trial in this indication; across indications, positive single-arm results and a failed Phase 3 [11] [VERIFIED — CT.gov] · Medium
Therapeutic window and safetyWide margin, no class liabilityManageable side effectsDose-limiting toxicity or a class liabilityToxicology, clinical safety, FAERS, class labels8No dose-limiting toxicity up to 30 mg; injection-site reactions the main event; no grade 3+ attributed to efti here [2] [8] [22] [VERIFIED — PubMed, Immutep 2025-11-13] · High
Data transparency and expert viewPeer-reviewed; supportive named experts (A.2b)Abstracts only; mixed viewsPress releases only; sceptical expertsPubMed, congresses, A.2b4EFTISARC-NEO exists as congress abstracts and press releases; no paper [23]. The one independent voice in A.2b places efti behind relatlimab on demonstrated efficacy (row Giri et al.); the investigator rows are the sponsoring department [UNVERIFIED — expert view score] · Low

Endpoints

Endpoint (full name)What it measuresScale / rangeBetter directionMCID / note
Pathologic response: percent tumour hyalinization/fibrosis (registered primary)How much of the removed tumour is scar tissue at surgery0–100% of the specimenHigherNo established minimal clinically important difference. ≥35% is conventionally a response; radiotherapy alone gives about 15%. Result: median 51.5% (n=38) [VERIFIED — CT.gov NCT06128863; FY26 annual report] [3] [5]
Health-related quality of life (what this catalyst reports)What patients report about pain, fatigue, function and wellbeing during treatmentInstrument not disclosed; if EORTC QLQ-C30, global health status 0–100HigherNot a registered outcome measure. On the QLQ-C30, about 10 points is conventionally meaningful [VERIFIED — CT.gov, for the absence]; instrument [UNVERIFIED] [3] [6]
Disease-free survival (DFS) (registered secondary)Time from surgery to any recurrence or deathMonthsLongerFollow-up to 2027-04-30. The endpoint that matters for approval [3]
Local recurrence-free survival (registered secondary)Time from surgery to recurrence at the original siteMonthsLongerSARC032’s benefit was mainly in distant, not local, recurrence [3] [10]
Distant metastasis-free survival (registered secondary)Time from surgery to cancer elsewhere in the bodyMonthsLongerThe endpoint the immune hypothesis predicts [3]
Overall survival (registered secondary)Time from surgery to death from any causeMonthsLongerImmature [3]
Objective response rate, RECIST 1.1 (registered secondary)Share of tumours shrinking by ≥30% on imaging before surgery0–100%HigherReported 19.0%; sarcomas often scar without shrinking [8]
Number of participants with adverse events (registered secondary)Safety, graded on CTCAE v5.0Counts by gradeFewerNo grade 3+ attributed to efti or pembrolizumab [8]
Number completing neoadjuvant therapy (registered secondary)Patients completing treatment and curative surgery per protocolCountHigherNot separately reported [3]

A.2b Named experts

Panel as of. 2026-10-17.

Investigators

The registry lists no principal investigator or site contacts for NCT06128863, and search_investigators on “Teterycz” returned no trials. One investigator is now named by a primary source: the company’s release names Paweł Teterycz as the first author of the ESMO 2026 abstract [6]. The two other names are carried from the 2026-08-19 sweep on inference from the sponsoring department’s authorship.

NameRole / affiliationTrial (NCT)Conflicts (party, kind, disclosed in, as of)Conflicts checked (source, date)SourceTag
Paweł TeteryczFirst author of the ESMO 2026 EFTISARC-NEO HRQoL abstract; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, WarsawNCT06128863Sponsor (Immutep), institutional: his department sponsors a trial Immutep supplies drug for. Disclosed in: Immutep release, 2026-07-24PubMed search_articles “Teterycz P[Author] AND sarcoma”, 56 hits, metadata for three, 2026-10-17: affiliations only, no conflict-of-interest field. CT.gov search_investigators “Teterycz”, 2026-10-17: no trials. No NIH RePORTER search (outside its scope)Immutep release 2026-07-24 [6]; PubMed, Czarnecka et al. 2026 [34][VERIFIED — Immutep release 2026-07-24, for the authorship]
Piotr RutkowskiHead of the sponsoring department, Warsaw. Not confirmed as an investigator by the registryNCT06128863 (institution only)Sponsor (Immutep), institutional, as above. Disclosed in: author affiliation, Wiśniewska et al. 2026, as of 2026-01-24PubMed PMID 41587647, 2026-08-19 and 2026-10-17: no conflict field. CT.gov search_investigators on the institution, 2026-08-19: none on this trialPubMed [31][UNVERIFIED — inferred from institutional authorship]
Paweł SobczukSponsoring department, Warsaw, and Vall d’Hebron Institute of Oncology, Barcelona. Corresponding author of a LAG-3 review. Not confirmed as an investigatorNCT06128863 (institution only)Sponsor (Immutep), institutional, as above. Disclosed in: Wiśniewska et al. 2026, as of 2026-01-24PubMed PMID 41587647, 2026-10-17: no conflict fieldPubMed [31][UNVERIFIED — inferred from institutional authorship]

Independent voices

One voice was found, and it comments on the LAG-3 drug class rather than on this endpoint. Nobody outside the sponsoring institution was found commenting on neoadjuvant pathologic response or quality of life with this combination.

NameAffiliationView (close enough to quote)As ofConflicts checked (source, date)SourceTag
Vinay K. Giri, David F. McDermott and Jacob ZaemesDivision of Medical Oncology, Harvard Medical School / Beth Israel Deaconess Medical Center, Boston”To date, the most significant demonstration of efficacy in targeting LAG-3 has been the use of relatlimab with the PD-1 inhibitor nivolumab in the treatment of advanced melanoma.” That places efti below the blocking antibody on demonstrated efficacy, and says nothing about sarcoma.2025-05-15PubMed PMID 40344213, 2026-08-19 and 2026-10-17: affiliations, no conflict field; none certified absent. No NIH RePORTER searchPubMed, Cancer 2025 [27][VERIFIED — PubMed get_article_metadata, 2026-10-17]

Judgement

Endpoint supportedBasis (one or two sentences)Tag
UNKNOWNNo independent voice has commented on either endpoint that matters: hyalinization or quality of life. The one voice found comments on the LAG-3 class, and the trial has no publication to attract commentary.[UNVERIFIED — judgement]

Dissent

Empty. Endpoint supported is UNKNOWN, so there is no claimed support for anyone to contest.

NameView (close enough to quote)Source

A.3 Go / No-Go questions

The next decision is go to Phase 3: the registration-directed trial targeted for 2H CY2027 [9].

#QuestionGo to Phase 2Go to Phase 3FilingAnswer (tagged, at most three points) [n]RatingConfidence
Target
T1Is proof of mechanism or principle established in people (target engagement, PD) with this candidate?●●Pharmacodynamic rises repeat across trials [2] [30]; in this trial interferon-gamma and CXCL9/10 rose and tracked response [5]. But TACTI-004’s product behaved differently [32] [VERIFIED — PubMed, Immutep releases]amberM
T2If the early population differs from the intended population, how is the evidence translated?●●It does not differ: EFTISARC-NEO enrolled the intended population [3] [VERIFIED — CT.gov]greenM
T3Is there a rationale for combinations, and is it pursued?●●●Yes: radiotherapy for antigen, efti for presentation, pembrolizumab to release the brake; tested together [3] [VERIFIED — CT.gov]greenH
Dose and drug
D1Is the exposure–response relationship and the therapeutic window defined for the intended regimen and route?●●●30 mg selected through Project Optimus [5]; no exposure–response model published, and none in sarcoma [VERIFIED — FY26 annual report]amberM
D2Is the dose and regimen compatible with the clinical and non-clinical safety data?●●●Yes. No dose-limiting toxicity at 30 mg across several hundred patients [2] [22] [VERIFIED — PubMed]greenH
D3Does the formulation deliver therapeutic exposure, and is it commercially viable (the final formulation for Phase 3)?●●●Open. 2,000 L product differs from 200 L product in N-glycan structure; a new 200 L run is contracted [9]. Which product EFTISARC-NEO used is not disclosed [VERIFIED — Immutep 2026-09-11]redM
D4Are intrinsic and extrinsic factors (organ impairment, drug interactions, ethnicity, body weight) characterised?●●No public record as of 2026-10-17 [23] [UNVERIFIED]amberL
Patient and design
P1Are the design and endpoints accepted by the FDA and EMA, clinically meaningful, competitive, and relevant for HTA bodies (B.3)?●●●No design disclosed; the primary endpoint is an unvalidated surrogate; no agency agreement announced [9] [VERIFIED — Immutep 2026-09-11]redM
P2What is the rationale for the population; is a selection biomarker validated, with a companion diagnostic plan?●●●Strong rationale: large, deep, high-grade tumours relapse most [10]. No biomarker needed or proposed [3] [VERIFIED — Lancet 2024; CT.gov]greenM
P3What is the probability of success of the next trial (effect-size assumptions, statistical power, trial simulation or assurance)?●●Not computable: no design, effect size or power is disclosed [UNVERIFIED]amberL
P4Has proof of concept with a positive benefit–risk balance been shown in the intended population?●●Proof of concept on a surrogate, against a historical control, in 38 patients [5] [VERIFIED — FY26 annual report]amberM
Benefit–risk
R1Is the safety database adequate for the indication (exposure, duration); are class effects or a REMS expected?●●Several hundred patients on efti overall, 40 in this setting; no class effect expected [2] [22] [VERIFIED — PubMed]amberM
R2Is the overall benefit–risk balance favourable against the current standard of care?●●Not established against pembrolizumab plus radiotherapy [10] [UNVERIFIED]amberL

Clinical data and design: 4.0 (direct). Basis: one single-arm trial of 38 evaluable patients met a surrogate endpoint (P4); D3 and P1 are red; no comparison against the current regimen exists (R2). · confidence Medium

A.4 Regulatory pathway

TopicQuestionsAnswer (tagged) [n]Where to look
PathwayWhich route: NDA or BLA, 505(b)(2), EU centralised MAA, conditional authorisation or accelerated approval? Is a confirmatory trial required, and is it feasible?A full BLA in the US and a centralised MAA in the EU would be needed. An accelerated approval on hyalinization has no precedent. A confirmatory DFS trial would take years [UNVERIFIED — judgement]FDA guidance, EMA procedural guidance
DesignationsBreakthrough Therapy, Fast Track, RMAT, Orphan Drug, priority review voucher (FDA); PRIME, orphan (EMA); Sakigake, orphan (PMDA): granted, or realistic?FDA Orphan Drug Designation in STS, 2026-04-15 [4]. Fast Track exists only in head and neck cancer and lung cancer [9]. No EU or Japanese designation found in the filings [VERIFIED — Immutep releases]Company filings, FDA and EMA registers
Agency alignmentEnd-of-Phase-2 meeting, scientific advice, SPA, parallel EMA and HTA advice: was the pivotal design agreed?No. The company cites “prior interactions” with the FDA in general terms; no meeting on an STS design is announced [9] [VERIFIED — Immutep 2026-09-11]Company disclosures, EMA scientific advice
PrecedentHave drugs been approved on the same endpoint and design in this indication? Any recent rejections in the class?No drug is approved before surgery in STS. Pembrolizumab’s SARC032 use is off-label: its label has no sarcoma indication [28]. Olaratumab, approved in advanced STS on a randomised Phase 2, was withdrawn in 2019 after its Phase 3 failed [35] [VERIFIED — DailyMed; G-BA]Drugs@FDA, EPARs, PMDA review reports
Review riskLikelihood of an advisory committee; safety signals; manufacturing inspection; co-approval of a diagnostic; post-marketing requirementsManufacturing comparability (D3) would be the central review risk. No diagnostic needed [UNVERIFIED — judgement]AdComm materials, CRL disclosures

Regulatory pathway: 4.0 (direct). Basis: an orphan designation is held, but there is no agreed design or endpoint, no approval precedent for the endpoint, and an open manufacturing question. · confidence Medium

Designations.

  • FDA Orphan Drug Designation, soft tissue sarcoma, granted 2026-04-15. It gives seven years of US market exclusivity for that indication if the drug is approved, fee exemptions and tax credits. It makes no efficacy judgement [4].
  • No Fast Track, Breakthrough Therapy or Special Protocol Assessment in soft tissue sarcoma. Efti’s Fast Track designations are in head and neck cancer and lung cancer [9].
  • No EU orphan designation was found in the company’s filings as of 2026-10-17. The EU register itself was not searched [UNVERIFIED].

A.5 Clinical operations

Development timeline for eftilagimod alfa in soft tissue sarcoma against the SARC032 competitor precedent, with the company events that bracket the catalyst

Source(s): CT.gov NCT06128863 [3]; SARC032 Lancet 2024 [10]; Immutep releases and filings [4] [9] [11] [33] [36]

Milestone dates. First patient in 2023-07-17. Registry primary completion 2025-04-30; topline announced 2025-05-27, 27 days later. Database lock not disclosed. Study completion, covering the 24-month follow-up, 2027-04-30 [3] [12].

Trials

TrialSponsor / whose drugDesign (arms, blinding, n)PopulationStatus / key resultLink
EFTISARC-NEOMaria Skłodowska-Curie National Research Institute of Oncology, with Immutep S.A.S. as collaborator; funded mainly by a €1.5M Polish government grant (about A$2.2M). Efti is Immutep’s; pembrolizumab is Merck’sPhase 2, single-arm, single-stage, open-label, one site, n=40Adults with resectable, non-metastatic, deep, grade 2–3 STS of limbs, girdles or superficial trunk; >5 cm or recurrentPrimary endpoint met: median 51.5% hyalinization (n=38) against a 35% target. Active, not recruiting. No results postedNCT06128863 [3] [5]
SU2C-SARC032 (competitor precedent)Academic, funded by Stand Up to Cancer and Merck. Pembrolizumab is Merck’sRandomised, open-label, two arms, 143 randomised (127 analysed)Stage III undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma of the limb or limb girdlePrimary endpoint met: DFS hazard ratio 0.61 (90% CI 0.39–0.96); 2-year DFS 67% against 52%NCT03092323 [10] [14]
TACTI-004Immutep S.A.S.Phase 3, randomised, double-blind, placebo-controlled, 756 plannedFirst-line advanced lung cancerStopped for futility 2026-03-13 at an interim of about 170 patients; registry still shows “active, not recruiting”NCT06726265 [11] [15] [37]
AIPACImmutep S.A.S.Phase 2b, randomised, double-blind, placebo-controlled, n=242 (226 treated)HR+ HER2-negative metastatic breast cancer on paclitaxelPFS not met (7.3 months both arms). Quality of life sustained on efti, deteriorated on placeboNCT02614833 [22] [16]
TACTI-002Immutep S.A.S.Phase 2, open-label, single-arm parts, n=187Lung cancer; head and neck cancerSecond-line head and neck: response rate 29.7%; second-line PD-(L)1-refractory lung: 8.3%NCT03625323 [30] [17] [38]
TACTI-003Immutep S.A.S.Phase 2b, randomised, open-label, n=171First-line head and neck cancerCompleted 2024-03. The basis of the 2026 head-and-neck focusNCT04811027 [18]
AIPAC-003Immutep S.A.S.Phase 2/3, randomised after open-label dose optimisation, n=72HER2-negative/low metastatic breast cancerTerminated; closed 2026-06-30NCT05747794 [19]
TACTI-melImmutep AustraliaPhase 1, open-label, dose escalation, n=24Metastatic melanomaResponse rate 33% (part A), 50% (part B)NCT02676869 [2] [20]

Pivotal programme

TrialSettingDesign / comparatorKey result [n]Use
None yetNeoadjuvant STSNot designed. Start targeted 2H CY2027, subject to design, regulators, manufacturing, partnering and resources— [9]Would support a US BLA and EU MAA
EFTISARC-NEONeoadjuvant STSSingle-arm; historical controlMedian hyalinization 51.5% [5]Proof of concept and the basis of the orphan designation; not pivotal

Effect by trial

Not applicable — no randomised trial of efti in soft tissue sarcoma exists.

TrialEndpointEffect (hazard ratio or other, named)95% confidence intervalnSource

Operational parameters

ParameterHigh (7–10)Medium (4–6)Low (1–3)Where to checkScoreBasis (tagged) [n] · confidence
Recruitment feasibilitySites and countries adequate for the disease’s prevalence; enrolment on or ahead of benchmarkAdequate, with competing trials for the same patientsRare population, few sites, enrolment delaysClinicalTrials.gov, EU CTIS3One site, one country. A randomised successor would need many sites; SARC032 needed 20 institutions and six years to randomise 143 [3] [10] [VERIFIED — CT.gov; Lancet] · Medium
Endpoint acceptanceRegulatory precedent in FDA or EMA guidanceNovel endpoint with documented agency agreementUnvalidated surrogateFDA and EMA guidance, EPARs3Hyalinization is unvalidated; DFS would need a randomised trial [3] [VERIFIED — CT.gov] · Medium
Design robustnessRandomised, controlled, agreed with the agencies (SPA)Adaptive or seamless, with a pre-specified interimSingle-arm without a robust external controlProtocol, SPA, scientific advice2Single-arm, historical control only [3] [VERIFIED — CT.gov] · High
Execution track recordSponsor met its prior milestonesMinor delaysRepeated delays, CRO or site problemsCompany history, 8-K filings, ../company.md C.1a6EFTISARC-NEO met every date with zero slips; the company met its TACTI-004 and Nasdaq dates. Against that, a Phase 3 failed on what the company now attributes to a product difference (../company.md C.1a) [VERIFIED — Immutep filings] · Medium

Resourcing sufficiency. For this catalyst, sufficient and nearly free: the trial is run and funded by the Warsaw institute, and what remains is an ePoster [5]. For the next step the answer inverts. The registration-directed trial is targeted for 2H CY2027 “subject to … partnering and resources” [9]. The company holds about A$61M net of debt-like items at 2026-06-30, guides cash “well into the first half of CY2028”, and has cut headcount (../company.md C.3) [39]. A multi-site randomised sarcoma trial would consume most of that. B.4c says more.

A.6 Probability of success

Base rate. baseRate({ phase: "phase2", area: "oncology", modality: "other" }) in lib/success-rates.mjs, run in node on 2026-10-17. Modality other has no category in the table, so the lookup falls back to the area level.

Base rate: 24.6% to the next phase · 10.8% to approval · source BIO 2021, Figure 2, p. 7 (Oncology) · fallback level area · Wong 2019 32.7% to the next phase and 11.6% to approval [WEB ESTIMATE — BIO/Informa/QLS 2021] [7]

Adjustments

FactorDirection (up / down)Evidence [n]Tag
Biomarker-selected population—not applicable: no selection—
Human genetic support for the targetdownNo genetic association between LAG3 and soft tissue sarcoma [26][VERIFIED — Open Targets, 2026-10-17]
Rare disease or orphan designationupFDA Orphan Drug Designation, 2026-04-15 [4][VERIFIED — Immutep release]
Randomised Phase 2 with a meaningful effectdownSingle-arm only; the comparison is historical [3][VERIFIED — CT.gov]
First-in-class, novel endpoint, or prior failures in the classdownFirst-in-class agonist; TACTI-004 stopped for futility; AIPAC missed PFS; AIPAC-003 terminated [11] [22] [19][VERIFIED — Immutep, PubMed, CT.gov]
Other, named: met primary endpoint by a wide marginup51.5% median against a 35% target [5][VERIFIED — FY26 annual report]
Other, named: no designed or funded next trialdownStart targeted 2H CY2027, subject to resources and partnering [9][VERIFIED — Immutep 2026-09-11]
Other, named: manufacturing comparability opendownN-glycan difference between production scales; new 200 L run contracted [9][VERIFIED — Immutep 2026-09-11]

Result

LowBaseHighBasis
To the next phase10%20%35%Below the 24.6% base rate: five downward factors against two upward. The low edge allows for the trial never being funded [UNVERIFIED — modelled]
To approval2%5%10%Below the 10.8% base rate for the same reasons, plus an unvalidated endpoint [UNVERIFIED — modelled]

These figures concern the program’s path to Phase 3 and approval. The October catalyst asks a narrower question, and the outcome call in Locked prediction explains its distance from the base rate.

A.7 Modality

  • Modality: other. An Fc fusion protein: the outer part of human LAG-3 fused to an IgG1 antibody tail, made in cultured cells and injected under the skin [2] [29].
  • Manufacturing is assessed in M below. Its CMC score feeds the Operations and CMC domain.

M. Manufacturing (CMC)

Short form: the program is at Phase 2, so M.1 and the M.6 score are written, and M.2 to M.5 are not applicable (01-rules.md rule 44). The manufacturing tier of the sweep does not apply yet.

M.1 Product and process

ElementDescribeThis asset [n]
Molecule or constructFor an antibody: isotype and expression system. For a conjugate: linker chemistry, payload class, conjugation site, DAR and its distribution. For a gene therapy: vector or capsid. For an RNA drug: the lipid nanoparticle. For a radioligand: the isotopeA dimeric fusion of the LAG-3 extracellular domains with an IgG1 Fc tail; a glycoprotein made in cultured mammalian cells. The 2026 root cause analysis found N-glycan differences between 2,000 L and 200 L batches [2] [9] [VERIFIED — Immutep 2026-09-11]
Drug substance stepsUpstream (growing the cells), downstream (purifying the product), payload and linker synthesis, conjugation, purification; in-house or CDMO for each stepMade by a third-party contract manufacturer; not named in the FY26 annual report. Ten GMP batches were made at 200 L; TACTI-004 used only 2,000 L material; a new 200 L run is contracted [5] [9] [VERIFIED — FY26 report; 2026-09-11]
Drug productFormulation (liquid or freeze-dried), presentation, device, stability and shelf life, refrigerated transport (cold chain)30 mg subcutaneous presentation used across the programme. Shelf life and presentation not disclosed [UNVERIFIED] [2]
AnalyticsThe critical quality attributes (such as DAR, free payload, aggregates, potency assay, vector genomes) and the release and characterisation methodsA proprietary MHC class II binding assay used as a GMP quality-control step, patented in FY26 [5]. The assay did not flag the glycan difference before TACTI-004 [VERIFIED — FY26 report; inference from the timing]
Companion diagnosticThe assay, its partner, and the timing of its co-approval (A.4)None needed [3]

M.2 Challenges by process step

Not applicable — short form before Phase 3.

Process stepTypical challengesStatus and readiness (tagged) [n]Rating

M.3 Regulatory CMC track record

Not applicable — short form before Phase 3.

ItemWhat to recordWhere to find itFinding (tagged) [n]

M.4 Network and capacity

Not applicable — short form before Phase 3. The company’s manufacturing network is in ../company.md C.1a.

TopicFinding (tagged) [n]

M.5 Modality questions

Not applicable — short form before Phase 3.

ModalityKey CMC and technology questionsAnswer for this asset (tagged) [n]

M.6 CMC score and top risks

Scored from M.1 and the public record, as the short form allows.

CriterionHigh (7–10)Medium (4–6)Low (1–3)ScoreBasis (tagged) [n] · confidence
Process robustness and CQAsValidated commercial process; well-defined CQAsProcess changes pending; comparability neededQuality problems recognised late2A structural difference between scales was found only after a Phase 3 failed [9] [VERIFIED — Immutep 2026-09-11] · Medium
Regulatory CMC recordNo CMC-related CRL or Form 483 issueMinor observations, resolvedA CMC CRL, a warning letter or a refusal6No public record of a CRL or Form 483, but the product has never been filed or inspected for approval [UNVERIFIED — absence] · Low
Capacity and supplyCapacity matched to demand; dual sourcingConstrained, or a single siteShortages, or a major over-capacity write-down4One contract manufacturer; the larger scale is under question; A$6.46M of its invoices on deferred terms [5] [VERIFIED — FY26 report note 18] · Medium
Cost of goodsCompatible with the price corridorMargin pressureCOGS threatens viability6A 30 mg dose is small for a biologic; the move back to 200 L may raise unit cost; no figure disclosed [UNVERIFIED] · Low

CMC score: 4.5 (mean of the four, from lib/scorecard.mjs)

Top-3 CMC risks. 1. The 200 L product may not restore the activity seen in earlier trials, or the regulator may require comparability work before a registrational trial [9]. 2. Which batch scale EFTISARC-NEO used is undisclosed, so its result may not transfer to future product [9]. 3. A single contract manufacturer, partly paid on deferred terms [5].


B. Commercial value

B.1 Treatment today and competitors

Treatment algorithm. For a large, deep, high-grade, resectable sarcoma of a limb or the trunk:

  1. Imaging, biopsy and grading. Small, superficial or low-grade tumours go straight to surgery.
  2. Radiotherapy before surgery, about five weeks. This is long-standing practice [10].
  3. Chemotherapy before surgery for selected subtypes; contested and not universal [UNVERIFIED].
  4. Pembrolizumab added to radiotherapy for selected subtypes, after SARC032 improved disease-free survival [10].
  5. Wide surgical removal, five to six weeks after radiotherapy.
  6. If the cancer returns, usually at a distant site, doxorubicin-based treatment and later lines.

Where efti would fit: step 4, as a third drug. It would replace nothing. It would sit on top of the regimen whose benefit was shown without it.

Competitors

Competitor (drug, company)StageKey data [n]Note (indirect comparison)
Pembrolizumab with radiotherapy (Merck; academic trial)Randomised trial complete, published; not FDA-approved in sarcoma2-year DFS 67% against 52%; HR 0.61; grade 3+ adverse events 56% against 31% [10]Indirect against EFTISARC-NEO: different endpoint (DFS against hyalinization), narrower subtypes, different follow-up
Radiotherapy then surgery (standard care)Standard2-year DFS 52% in SARC032’s control arm; median hyalinization about 15% historically [10] [5]The historical 15% is not from a concurrent control
Other LAG-3 drugs (relatlimab and others)Approved in melanoma onlyNot tested in sarcoma [27]They block LAG-3; efti activates the MHC class II side

Competitive position

MetricHigh value (7–10)Medium value (4–6)Low value (1–3)Where to checkScoreBasis (tagged) [n] · confidence
Mechanism differentiationFirst-in-class, or clearly best-in-classNext-generation improvementMe-tooPublications, the competitor list above8The only MHC class II agonist in clinical development [27] [40] [VERIFIED — PubMed] · High
Timing against competitorsMore than 12 months ahead of the nearest competitorWithin 6 to 12 monthsLagging by more than 12 monthsClinicalTrials.gov2Pembrolizumab plus radiotherapy published randomised data in 2024; efti’s next trial would start in 2H CY2027 at the earliest [10] [9] [VERIFIED — Lancet; Immutep] · High
Clinical data against competitorsSuperior efficacy, safety or convenience (B.1a)ComparableInferiorPublications, congress data5Safety looks better in a cross-trial view; efficacy cannot be compared (no DFS) [10] [8] [UNVERIFIED — indirect] · Low
IP and exclusivity10 years or more after launch (composition of matter)5 to 10 years, or method of use onlyUnder 5 years, or pending onlyOrange Book, Purple Book, patent databases5Method-of-use patent on efti with a PD-1 inhibitor to 2036 (carried from the 2026-08-19 sweep); acquired composition patents amortised over their legal life; orphan exclusivity of 7 years on approval; biologic exclusivity if approved [4] [5]. The 2036 patent [UNVERIFIED — carried from the 2026-08-19 sweep, not re-read]; the rest [VERIFIED — FY26 report; Immutep] · Medium

Strategic insight. No sourced first-mover observation for neoadjuvant sarcoma exists. The illustrative oncology figure is roughly 3.2 times the peak-sales potential and 1.8 times the development risk for a first mover with a novel mechanism [UNVERIFIED — illustrative]. Efti is first in its mechanism and last in its setting. It wins only if it is the best way to make an already-working immune regimen work better. The investment case rests on one fact: that the 51.5% median hyalinization reflects something efti added, not what pembrolizumab plus radiotherapy does alone. Nothing yet separates the two.

B.1a Efficacy against side effects

Every comparison here is indirect (01-rules.md rule 17). The patients, subtypes, follow-up and side-effect definitions differ between trials. Efti is not placed on the chart: EFTISARC-NEO has reported no disease-free survival, so there is no point on the shared efficacy axis. Its data are in the table.

Efficacy against side effects, resectable soft tissue sarcoma

Source(s): SU2C-SARC032 [10]. Scaling: x = 2-year DFS as a fraction (0.52 and 0.67); y = 1 minus the grade 3+ adverse-event rate (0.69 and 0.44). Indirect comparison across trials (rule 17).

IndicationRegimen (trial)Efficacy (endpoint, value)Grade 3 or higher adverse events (%)Adverse event definition (any cause, treatment-emergent or treatment-related)Source
Resectable STSRadiotherapy then surgery (SARC032 control)2-year DFS 52%31%As reported in the Lancet abstract, grade 3 or higher adverse events[10]
Resectable STSPembrolizumab with radiotherapy then surgery and adjuvant pembrolizumab (SARC032)2-year DFS 67%; HR 0.6156%As above[10]
Resectable STSEfti with pembrolizumab and radiotherapy, early data (EFTISARC-NEO, single-arm)Median hyalinization 51.5%; DFS not reportedNot disclosed (no grade 3+ attributed to efti or pembrolizumab)Treatment-related only[5] [8]

B.2 Addressable market

ComponentHow it is estimatedAssessment guideThis asset (tagged)Source [n]
Drug-treated patientsPrevalence or incidence × diagnosis rate × treatment rate × eligible shareMore than 100,000 (US, EU5, Japan) is a premium threshold for a common disease; judge an orphan market relative to its areaAbout 5,000–7,000 patients a year in the US and EU5, carried from the 2026-08-19 build: about 13,000 US STS cases a year × 60% localised × about half in limbs or trunk × half to 60% grade 2–3 and >5 cm, and the same fractions on about 23,400 EU cases. Each fraction after the first is an assumption[WEB ESTIMATE — SEER and RARECARE via web search, 2026-08-19]; fractions [UNVERIFIED — modelled]
ExclusivityPatent term + extensions (PTE, SPC) + regulatory, orphan or paediatric exclusivityYears of exclusivity after launch; the generic or biosimilar entry dateOrphan exclusivity 7 years from US approval; combination patent to 2036; US biologic exclusivity of 12 years if approved as a new biologic. On a 2033 launch, about 7 to 12 years[4] [5] [UNVERIFIED — modelled on an assumed 2033 approval]
Reimbursement precedentApprovals and payer decisions in two or more major marketsPositive NICE or CADTH guidance for a drug like this oneNone for efti. Analogues: olaratumab (advanced STS) recommended within the Cancer Drugs Fund by NICE in 2017, and later withdrawn [41][35] [41]
Price corridorComparator and analogue prices; a value-based priceWorked out in B.3US$30,000–80,000 per nine-week course, modelled (B.4a)[UNVERIFIED — modelled]
Patient and system impactHospitalisations, caregiver burden, HRQoLThe size of the effect and the evidence for itThe one row this catalyst speaks to: whether nine weeks of injections around radiotherapy preserve quality of life[6]

B.3 Payers and price

Per market

MarketIn scope?Expected outcomePrice implicationKey riskSource [n]
United States: ICER benchmark; Medicare negotiation exposure (IRA timing, orphan exclusion)AlwaysNo ICER assessment exists for this setting. As an orphan-only biologic, efti would be excluded from Medicare negotiation while all its approved uses stay orphan; pembrolizumab was reportedly not selected for 2028 because of the 2025 orphan-exclusion changeNo near-term negotiation pressurePayers may restrict an add-on with single-arm data[42] [43] [44]
EU joint clinical assessment (JCA)YesA JCA would apply to an EU filing (mandatory for new oncology medicines since January 2025). Its comparator would be pembrolizumab plus radiotherapy or radiotherapy aloneWeak relative-effect evidence without a randomised trialA PICO built around a randomised comparator[45]
Germany: G-BA and IQWiG (AMNOG)YesOrphan benefit deemed while under the €30M revenue limit; quantification needs comparative dataPrice capped near the comparator without proven added benefitThe olaratumab precedent: benefit deemed in 2017, decision rescinded in 2020 after withdrawal[35]
UK: NICEYesA positive recommendation would need DFS against the comparator; managed access is possibleCost per QALY within £25,000–35,000 [UNVERIFIED — illustrative]TA185 recommended trabectedin only with a cost cap[41] [46]
Japan: ChuikyoRetained, not modelledNot assessed: no plan for Japan is announced——[47]

Questions

QuestionAnswer (tagged) [n]
Comparator: does the pivotal trial compare against what payers require (the G-BA’s appropriate comparator, the NICE scope, the JCA’s PICO, the US standard of care)? If not, is a credible bridge planned, such as an indirect comparison or an external control?No. EFTISARC-NEO has no comparator. No bridge is planned [VERIFIED — CT.gov] [3]
Endpoints and certainty: patient-relevant endpoints (mortality, morbidity, quality of life, safety) or surrogates? Will payers discount the design (single-arm, crossover, immature data)?Surrogate (hyalinization) from a single-arm trial; payers will discount it heavily. The HRQoL data are patient-relevant but unregistered [VERIFIED — CT.gov] [3]
Supplementary evidence: quality-of-life data (EQ-5D), early payer advice (EU joint scientific consultation, G-BA, NICE), real-world or natural-history data, an early cost-effectiveness model?HRQoL data exist (this catalyst); the instrument is undisclosed, and EQ-5D is not known to be collected. No payer advice is announced [UNVERIFIED] [6]
Value against price: a realistic G-BA added-benefit category; cost per QALY against the NICE threshold; the ICER price benchmark. Do they support the target price against the comparator?Not assessable without comparative efficacy [UNVERIFIED]
Access conditions: likely restriction to sub-populations, managed access or confidential discounts, post-launch data obligations?Likely restriction to subtypes where pembrolizumab is used, managed access, and confirmatory DFS obligations [UNVERIFIED — judgement]
US comparator annual cost (list price), the ICER benchmark, and the Medicare negotiation timing for this drug (small molecule 7 years, biologic 11 years after approval; orphan exclusion)Pembrolizumab’s US list price was not read this sweep. No ICER benchmark. Efti would be a biologic (11 years), likely excluded while orphan-only [44] [WEB ESTIMATE — Milliman, secondary, read 2026-10-17]

Market access criteria

CriterionHigh (7–10)Medium (4–6)Low (1–3)ScoreBasis (tagged) [n] · confidence
Comparator alignmentRandomised trial against the payers’ comparatorRobust indirect comparisonPlacebo or single-arm only2Single-arm only [3] [VERIFIED — CT.gov] · High
Endpoints and certaintyHard endpoint, mature, randomisedSurrogate, immatureUnvalidated surrogate, single-arm2Unvalidated surrogate, single-arm [3] [VERIFIED — CT.gov] · High
Supplementary evidence planQuality of life (EQ-5D), payer advice, real-world evidence, a cost-effectiveness modelPartialNot addressed4HRQoL collected; nothing else known [6] [VERIFIED — Immutep 2026-07-24] · Medium
Value for money at the target priceWithin the NICE threshold, or at or below the ICER benchmarkNeeds a discountFar above the thresholds4No price and no comparative effect; an add-on would likely need a discount [UNVERIFIED] · Low
Payer precedentPositive, with a premium priceRestricted or mixedRejected, or priced at the comparator4Mixed: olaratumab’s orphan benefit was deemed and later rescinded; trabectedin recommended with a cost cap [35] [41] [46] [VERIFIED — G-BA, NICE] · Medium

Market Access Score: 3.2 (mean of the five, from lib/scorecard.mjs)

Payer decisions

MarketIndication / evidenceOutcome (body’s own words, date)Main reasonSource [n]
GermanyOlaratumab with doxorubicin, advanced STS; randomised Phase 2Added benefit deemed proven as an orphan drug (2017-05-18); decision rescinded 2020-01-16 after the EU authorisation was revoked on 2019-07-19Orphan rule; then the confirmatory Phase 3 failed[35]
UKOlaratumab with doxorubicin, advanced STSRecommended for use within the Cancer Drugs Fund (TA465, 2017-08-09)Immature survival data[41]
UKTrabectedin, advanced STS after anthracyclinesRecommended where the manufacturer caps the cost after the fifth cycle (TA185, 2009; updated 2021-02)Cost-effectiveness[46]
JapanTrabectedin, STSListed on the NHI price list 2015-11-26—[47]

Two of these four decisions are older than the template’s seven-year window. They are kept because no newer payer decision in soft tissue sarcoma was found, and the olaratumab rescission (2020) is inside the window.

B.4 Valuation and financing

B.4a Peak sales

Built bottom-up for the STS indication only, the US and EU5 only, and conditional on an approval that is not yet funded. It excludes every other efti indication, all partner territories and IMP761. Launch is assumed in 2033: a trial starting 2H CY2027 with a DFS endpoint would read out around 2031 [UNVERIFIED — modelled]. The build is carried from the 2026-08-19 version unchanged, because nothing in this sweep moved its inputs.

ScenarioAssumptions (patients × price × share × duration)Estimate (USD/year at peak)Basis / tag
Low6,000 patients × 10% penetration × US$30,000 per nine-week course × one course~US$18MUse only at high-volume sarcoma centres [UNVERIFIED — modelled; efti has never been priced]
Base6,000 × 25% × US$50,000 × one course~US$75MAdoption at the referral centres that treat most of this population [UNVERIFIED — modelled]
High6,000 × 40% × US$80,000 × one course~US$192MGuideline inclusion alongside pembrolizumab [UNVERIFIED — modelled]

Rejected input, kept as an audit trail. The peak-sales search found one figure: US$79M a year by 2038 for efti across all indications, from a paid model quoted by a trade site [48]. It is not broken out by indication and is not used. The 2026-08-19 sweep also rejected an “AU$1.30 consensus” target as a stale pre-failure figure (01-rules.md rule 6); that rejection stands.

B.4b Value

ScenarioeNPV (USD)Assumptions (discount rate, costs, royalties and milestones, loss of exclusivity, probability of success)Tag
Lownot computedThe registrational trial’s cost and design are undisclosed[UNVERIFIED — declined]
Basenot computedAs above[UNVERIFIED — declined]
Highnot computedAs above[UNVERIFIED — declined]

Why no range, kept from the 2026-08-19 version. That version declined because two inputs were unbounded: the probability of approval and the cost to approval. A.6 now bounds the first (2–10%). The second is still undisclosed, and so is whether the company or a partner would bear it. A range built on an invented trial cost would look like analysis and carry none.

B.4c Funding

QuestionAnswer (tagged) [n]
Capital needed to the next decision pointEssentially nil for this catalyst: the trial is grant-funded and the ePoster is the investigators’ [5] [VERIFIED — FY26 annual report]
Capital needed to approval, and the funding planA multi-site randomised trial with a DFS endpoint; cost not disclosed. The plan is “subject to … partnering and resources”, and the company is “in preliminary discussions with other parties” [9] [VERIFIED — Immutep 2026-09-11]
Cash runway against those needs (../company.md C.3)Runway guided “well into the first half of CY2028” (../company.md C.3). A trial starting 2H CY2027 would begin with about two to three quarters of cash left at the guided rate [UNVERIFIED — derived from guidance]
Financing need and dilution risk before the next decision (../company.md C.3, dilution history)High before the 2H CY2027 trial start, low before this catalyst. No equity raised in 24 months. A raise with the ADS at about 0.73 times the cash floor would be very dilutive (../company.md C.3, C.4) [UNVERIFIED — judgement]

B.4d Launch, partnering, rights and economic share

QuestionAnswer (tagged) [n]
Launch capability: can the company launch alone, or must it partner?Must partner. No product has ever been sold and there is no sales force (../company.md C.1a)
Partnering history and comparable deal termsDr. Reddy’s licence of 2025-12-08: US$20M upfront (US$10M repaid in June 2026), up to US$349.5M in milestones, double-digit royalties. Dr. Reddy’s was consulted on and “is supportive of” the 2026-09-11 focus [1] [5] [9]
Commercialisation rights: retained, split, or out-licensed?US, Europe (incl. the UK) and Japan retained; other territories out-licensed (Dr. Reddy’s; EOC Pharma in Greater China) [1]
Economic share1.0 for the modelled US and EU5 sales, because those territories are fully retained today. A future launch partner would reduce it; no such deal exists, so 1.0 is the honest figure for an upper bound [VERIFIED — Dr. Reddy's release, for the retained territories]

Visual 4: scenario chart

Annual sales by scenario

Source(s): B.4a assumptions; launch year 2033 and the uptake shape are modelled [UNVERIFIED — modelled] [9]. Lines, from bottom: low, base, high.


C. Risk

Framing questions

  1. Does the development plan support the target product profile claims (A.1)? Not yet. The profile claims an effect on top of pembrolizumab plus radiotherapy. Only a randomised trial against that backbone can support it, and that trial is a 2H CY2027 target, not a plan.
  2. Would the identified risks change the target product profile? Yes, two of them. The backbone confound attacks the efficacy row. The manufacturing finding attacks the dose and formulation row: the product in a future trial may not be the product that produced 51.5%.
  3. If a risk cannot be mitigated, is the asset still differentiated from competitors? On mechanism, yes: it stays the only MHC class II agonist. Without controlled efficacy that is a scientific distinction, not a commercial one.
Risk groupCoversTime / quality / cost riskLikelihoodImpactMitigationSource [n]
Science and clinicalResearch, biomarker, clinical pharmacology, clinical efficacy, drug safetyQuality: the effect may belong to the backbone; TACTI-004 failed. Time: DFS matures from 2027highhighA randomised trial against pembrolizumab plus radiotherapy. Safety is the strongest row: no near-veto signal[10] [11] [8]
Non-clinicalDMPK, safety pharmacology, toxicologyNo signal in several hundred patientslowlowNone needed[2] [22]
RegulatoryPathway, endpoints, review, post-marketing requirementsQuality: no agreed endpoint; hyalinization has no precedent. Time: agency meetings not yet heldmediumhighFDA interaction on a DFS design before 2H CY2027[9]
CMC and supplyProcess, scale-up, comparability, capacity, diagnostics (from M)Quality and time: 2,000 L product differs from 200 L product; a comparability programme may be needed. Treated as a potential near-veto until the root cause closeshighhighNew 200 L run contracted; root cause analysis ongoing[9]
IP and legalPatents, freedom to operate, litigation, licencesMethod-of-use protection only; three investor-notice releases by a law firm after TACTI-004, no filed complaint foundmediummediumOrphan and biologic exclusivity if approved[5]
Access and commercialEvidence and value, payers, pricing, competitionQuality: single-arm surrogate data; cost: an add-on price on an expensive backbonehighmediumHRQoL data (this catalyst); a randomised trial[35] [41]
Execution and financingProject management, clinical operations, funding, partnersCost and time: the next trial is unfunded; runway to H1 CY2028; ADS at 0.73 times the cash floorhighhighPartner discussions; Dr. Reddy’s support; cost cuts[5] [9]

Risk profile: 3.0 (direct, 10 = low risk). Basis: three groups sit at high likelihood and high impact (science and clinical, CMC and supply, execution and financing); only non-clinical risk is low. · confidence Medium

Visual 5: risk heat map

Risk heat map

Source(s): the risk table above [5] [9] [10] [11]

Top-3 risks. 1. The backbone confound: the effect may be pembrolizumab’s [10]. 2. Manufacturing comparability between production scales [9]. 3. An unfunded registrational trial against a runway to the first half of CY2028 [5] [9].


D. Look-back

Not applicable until settled. The look-back is written at settlement in lookback.md beside this file (06-prompts.md § Settlement).


Readout

Sources

KindWhere it comes fromWhat it is worthValue (or null)TagNote
bpiqfetch_company_drugs, fields catalyst_date and catalyst_date_textThe one source every program has. On most rows it is built from period text, so on its own it is the latest plausible date (a ceiling), not an estimate.2026-10-19[VERIFIED — BPIQ fetch_company_drugs, 2026-10-17]catalyst_date_text is “October 19, 2026”: it names a day, so catalyst_date_is_exact is true. Unchanged since 2026-08-19.
ctgovCT.gov get_trial_details, field primary_completion_dateIndependent of the company’s own messaging. Known to the month. It moves when the trial moves.2025-04-30[VERIFIED — CT.gov NCT06128863, 2026-10-17]Dates the primary readout, which happened in May 2025. It bounds nothing about this secondary analysis. Study completion 2027-04-30 covers the 24-month follow-up.
companyfetch_company_press_releasesThe company’s most recent dated statement. Also the source of the Date slippage table below.2026-10-19[VERIFIED — Immutep release 2026-07-24]”The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026”, online at 00:05 CEST. That is 18:05 on Sunday 18 October in New York, so the first US session able to react is 2026-10-19. No later release moved the date [6].
congressdata/congresses.json, only when the company has said it intends to present there (02-connectors.md § Data limits)Answers where the result will be presented.2026-10-23/2026-10-27[VERIFIED — data/congresses.json, confirmed against esmo.org]ESMO Congress 2026, IFEMA Madrid. ePoster 3788eP; the display day is not disclosed [49].
modelledTrial arithmetic, see belowThe only estimate independent of anyone’s guidance.2025-06-30/2025-08-31[UNVERIFIED — modelled, default lag]Uninformative, and recorded anyway: see below.

The modelled estimate. Registry primary completion 2025-04-30, plus the default lag of two to four months (01-rules.md rule 34; data/benchmarks/readout-lag.json holds no matching entry), gives 2025-06-30 to 2025-08-31. That window closed over a year ago. The method dates the trial’s primary readout, which came on 2025-05-27, faster than the default lag. It cannot date a congress presentation of a secondary analysis.

An observation this analysis produced but may not write down, carried from 2026-08-19. EFTISARC-NEO gives a confirmed lag of 27 days: primary completion 2025-04-30, topline 2025-05-27, both from primary sources. data/benchmarks/readout-lag.json is outside this lane and was not touched.

Window

EarliestLikeliestLatestPrecisionConfidence
2026-10-192026-10-192026-10-19DAYHIGH

Basis. One moment discloses the numbers: the full abstract online on 2026-10-19 [6]. The ePoster on 23–27 October shows the same content and is not a second readout. Precision is DAY because the company names the day; confidence is HIGH because the trial is complete, the abstract is accepted and the date is a publisher’s calendar.

Corrected after the first lock, kept from the 2026-08-19 version. The window was first written with latest at 2026-10-27, which counted the congress tail twice and claimed DAY precision over eight days. The window was narrowed, not relabelled.

Disagreement. CONSISTENT. BPIQ’s 2026-10-19 and the congress’s 23–27 October are two moments of one event, both stated in the company’s release of 2026-07-24.

Date slippage. Two dated statements, zero slips. Nothing since 2026-07-30 restated or moved the date; the strategy release of 2026-09-11 does not mention it.

As ofGuidance text
2026-07-24”The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026”
2026-07-30”EFTISARC-NEO HRQoL ESMO 2026 presentation reiterated; disease-free survival follow-up continues” (BPIQ note)

Attribution

Status.

StatusMeans
CONTAMINATEDAt least one conflict is confirmed. The stock-direction call below is not presented as attributable to this program alone.

Conflicts

bpiq_drug_idLabelDateAnalysed?Gap (days)Confirmed?
18203IMP761 (LAG-3 agonist)2026-12-31No0Yes

Computed with attributionFor from lib/clustering.mjs over this ticker’s nine pipeline rows at CATALYST_CLUSTER_MIN_MONTHS = 6, for bpiq_drug_id 17452, on 2026-10-17. Row 13791 (TACTI-004) no longer carries has_catalyst, so it contributes nothing.

Note. IMP761’s next update is guided to “H2 2026”. With no day named, the computation widens it to 2026-07-01 to 2026-12-31, which contains this readout, so the gap is zero. The conflict is confirmed because this side has DAY precision. Two non-drug events also sit in the stock window and are invisible to the computation. The September-quarter activities report is due by 2026-10-31 under the ASX’s quarterly reporting rule (last year’s came on 2025-10-30), and the FY26 Form 20-F is due by 2026-10-31 (last year’s was filed 2025-10-24). Either can carry cash, burn, root-cause or IMP761 news. The Nasdaq deadline that contaminated the 2026-08-19 window is gone: the ratio change cured it and Nasdaq closed the matter on 2026-10-12 [50]. No move in the window can be credited to the HRQoL abstract alone.


Market and timing for this event

  • Plain takeaway. A secondary quality-of-life abstract publishes in two days, on a trial whose real result came out seventeen months ago. The stock trades at US$3.20, 27% below its cash floor of US$4.37, after falling 60% since the last lock. It has no readable options, a Nasdaq line of about US$86,000 a day, and a quarterly report due inside the window.
  • Months to this catalyst. 0.1 months: two days, from 2026-10-17 to readout.window.earliest of 2026-10-19 (rule 23). readout.precision is DAY, so this is a distance to a known date.
  • Expected move around this event. A bracket, not a figure, because ../company.md C.6 records no readable chain. Bracket: roughly ±5% to ±25%. The class averages are +12% / −16% for Phase 2, +9% / −9% for oncology, and an amplitude of 7% for single-arm designs [WEB ESTIMATE — IQVIA 2024] [51]. They are measured on primary readouts, and this is not one. The specific facts outrank them: the median reaction to this ticker’s eight comparable data events is +1.8%, while the ADS now trades about US$86,000 a day, so modest order flow moves it 5–10%.
  • Nearest comparable past reaction. ../company.md C.7’s 2025-10-20, −1.68%: the same trial’s full primary data at ESMO 2025, already public in headline. It is the closest analogue because it is the same trial, the same congress and the same information structure. The 2026-07-24 acceptance of this very abstract moved the stock −2.56%. The 2026-04-15 orphan designation, +80.65%, is the reminder that sarcoma news can move this stock violently; it was a regulatory fact, not data.
  • Materiality. ../company.md C.2 records this program as meaningful at the programme level, immaterial at the event level. The stock call is made consistent with the event (rule 27).
  • Date slippage. Zero slips (Readout, above).

Spot. US$3.20 per ADS, the settled close of 2026-10-16, read from the price cache through lib/prices.mjs; cited from ../company.md C.4. It is not an intraday figure: the cache was fetched on 2026-10-17, after that session closed.

Comparison with the superseded record. The 2026-08-19 record locked US$0.40 on the old basis of 1 ADS = 10 ordinary shares. Times 20, that is US$8.00 on today’s basis. Today’s US$3.20 is 60% lower. The 2026-08-19 bar in the cache reads 0.3964 because an intraday price was frozen there; the source’s close for that day is 0.39 (7.80 on the new basis).

Cash floor.

Cash floor (USD per share)Cash, debt, quarterly burn (as of)Event dateEconomic share countResidual pipeline valueTag
US$4.37 per ADSCash US$47.93M (A$68.87M at 0.69588); debt-like items US$5.23M (deferred manufacturing accrual and leases, A$7.51M); burn US$8.35M per quarter (A$12M, modelled); as of 2026-06-30; 1.22 quarters to the event2026-10-197,452,053 ADS-equivalentsUS$0: no other C.2 row is rated meaningful (every unanalysed row is unfilled)Cash and debt [VERIFIED — FY26 annual report]; FX [WEB ESTIMATE — ECB reference rate via frankfurter, 2026-10-16]; burn [UNVERIFIED — modelled from guidance]. Computed by cashFloor in lib/edge.mjs

Scenario prices

ScenarioLowHighAnchors (each named, tagged, with its kind)Basis
PositiveUS$3.05US$4.001. own_past_moves: median window move of the eight clean, non-registrational data events in C.7, +1.81%, implying US$3.26 [VERIFIED — data/prices/IMMP.json via lib/prices.mjs; event dates from BPIQ and the press feed]. 2. cash_floor: US$4.37, from cashFloor above [VERIFIED — FY26 report; burn UNVERIFIED — modelled]The low edge is the price if the abstract just meets the positive definition, the “met expectations” bucket. It sits 5% below spot because three of this ticker’s last four positive data events closed lower (2025-10-20 −1.7%, 2026-06-04 −7.2%, 2026-07-24 −2.6%). The high edge is the “significantly exceeded” bucket: quality of life improved, with a release that adds follow-up or a funded trial. It stops below the cash floor; the +80.65% orphan-designation move is the ticker’s maximum and is not used. Class calibration: the +12% Phase 2 average [WEB ESTIMATE — IQVIA 2024] is not applied at full weight, because this is a secondary analysis.
MissUS$2.30US$3.001. cash_floor: US$4.37 [as above]. 2. own_past_moves: the worst comparable data-event window, 2026-06-04, −7.23%, implying US$2.97; and the reaction to the 2026-09-11 strategy release, −30% over the next ten sessions (0.37 to 0.26), implying US$2.24 [VERIFIED — data/prices/IMMP.json via lib/prices.mjs]The whole row sits below the cash floor. Three reasons. The floor counts burn only to 2026-10-19, while the company plans to spend its cash on efti trials to 2028 and returns none. The market already values the company 27% below the floor. And the ADS line has slid 32% since the ratio change. A meaningful deterioration in quality of life would be new negative information about the one property the regimen’s case rests on, in one of the two indications left. The miss sits deeper than the positive lifts, as the Phase 2 ratio of 1.3 suggests [WEB ESTIMATE — IQVIA 2024].

Expectation benchmark. Quality of life maintained through the neoadjuvant period, which is what the sponsor’s decision to submit and announce the abstract implies investors already expect. Beating it means global health status improved, or a release adding a funded next step [UNVERIFIED — judgement, from A.1's payer and safety rows].

Expected value. 0.85 × US$3.525 + 0.15 × US$2.65 = US$3.394, +6.05% against spot US$3.20. Method: our probability applied to the midpoint of each range. This is arithmetic, not advice, and not a price target.

Break-even probability.

Break-even pointBreak-even range (low–high)Our probability (band)Clearance (pp)Call (callFromBands)Evidence for the gap (each named and tagged)
62.9%20.0%–120.0%85% (72–92%)noneno-edgenone

Computed by breakEven and callFromBands in lib/edge.mjs. The band [72, 92] overlaps the range [20.0, 120.0], so the call is no-edge whatever the evidence. The range’s top sits above 100%: at both low edges, even a certain positive would not justify today’s price, because the positive low (US$3.05) sits below spot. The expected value is above spot, but the band test does not clear, and rule 42 lets the test, not the expected value, decide.

What a positive result can be worth.

Value at approval (low / base / high)Ceiling priceAllowance (1.5x, or 3x with a named exception)Ratio to market cap
US$36M / US$262.5M / US$960MUS$70.701.5x: US$104.46 (3x would be US$205.71; no exception claimed)5.8334

Computed by commercialCeiling in lib/edge.mjs from B.4a, an economic share of 1.0 (B.4d), the 2–5 sales multiple [UNVERIFIED — default] and a 52.4% probability of approval after a positive Phase 2 [WEB ESTIMATE — BIO/Informa/QLS 2021], over 7,452,053 ADS-equivalents and a US$23.58M market capitalisation (../company.md C.4). The 1.5x multiplier is a default [UNVERIFIED — default]. The positive high of US$4.00 sits far under the cap. The ratio is large because the company is valued below its cash, not because this catalyst could unlock the value.

Run-up

No run-up call. This is not rule 39. readout.precision is DAY and readout.confidence is HIGH, so the date_confidence driver would score 100. The call is withheld because no exit rule can resolve after the entry. The entry would be this lock: 2026-10-17, at the 2026-10-16 close. The latest permitted exit, T-1 trading day before readout.window.earliest of 2026-10-19, is 2026-10-16 itself. T-2 is 2026-10-15 and T-5 is 2026-10-12. Every exit in EXIT_RULES falls on or before the entry’s own price date, so the holding period is zero or negative. resolveExit in lib/runup.mjs returns null against this cache for the same reason: its last bar predates the window. A run-up band from such a position would be a band of nothing. The field is declared in not_carried_over (05-prediction-protocol.md § Holes are declared, never filled).

Why it happened. The T-1 cadence gate opened on 2026-09-19. This refresh runs four weeks later, two days before the readout. A position “has to exist before the window opens” (rule 35), and two days before a Monday readout, with no trading session left, it cannot.

The superseded record’s run-up call is still live history. It entered at US$0.40 on 2026-08-19 with a T-5 exit, which resolves to 2026-10-12 (close US$3.67, new basis). Settling it needs a spot_scale of 20 for the ratio change effective 2026-09-28; on that basis the move is about −54%. That is for the settlement to compute, from the cache, when asked.

Priority score not computed · formula_version not applicable

Settlement. Not applicable: no run-up call is locked on this record.

Verdict

What I would do. Watch.

Why. The date is certain and the event carries little information: a quality-of-life poster on a 40-patient trial whose result is seventeen months old. What decides this program now is whether a randomised sarcoma trial gets designed and funded for 2H CY2027, and whether the 200 L product behaves like the product that worked. The stock already trades 27% below its cash floor, so the market prices the whole pipeline below zero; a favourable poster is unlikely to change that on its own.

What would change this. To the upside: a funded or partnered randomised trial in soft tissue sarcoma, or a completed root cause analysis showing the 200 L product restores earlier activity. To the downside: a reported meaningful deterioration in quality of life, or an equity raise at a price this far below cash.

What to watch.

  • 2026-10-19, 00:05 CEST (Sunday 18:05 in New York): the full abstract on the ESMO 2026 website. Read the instrument, the completion rate of the questionnaire and the timepoints.
  • 2026-10-23 to 2026-10-27: ESMO Congress 2026, ePoster 3788eP, and any Immutep release.
  • By 2026-10-31: the September-quarter activities report (cash, burn) and the FY26 Form 20-F.
  • Undated: completion of the TACTI-004 root cause analysis; any IMP761 update (H2 2026).
  • 2026-11-27: the annual general meeting.
  • 2027-04-30: EFTISARC-NEO study completion, the first point where disease-free survival can be read.

Locked prediction

  • Outcome-direction (will the readout succeed on its primary endpoint?): positive — probability 85%, band 72–92% [UNVERIFIED — modelled]. This is the probability that the settlement definition below is met: the abstract, ePoster or Immutep release reports quality of life maintained or improved, with no statistically significant and no clinically meaningful deterioration. It is high for four reasons. No grade 3 or higher toxicity was attributed to either study drug. AIPAC, a randomised trial of efti, found global health status sustained on efti and worse on placebo [22]. The regimen adds injections to visits already scheduled. And the sponsor chose to submit and announce this abstract. It is capped below 90 for three reasons: the endpoint is unregistered, the instrument is undisclosed, and nine weeks of therapy around radiotherapy and surgery can produce a real dip at one timepoint, which in 38 patients could reach statistical significance. Nothing in this sweep moved the figure from the 2026-08-19 value. No third party has published a probability on this event.
  • Base rate 24.6% (to the next phase, BIO 2021 Figure 2 p. 7, Oncology) — distance +60.4 pp, because the base rate counts Phase 2 programs that advance to Phase 3, while this definition asks only whether reported quality of life did not deteriorate meaningfully, in a trial whose efficacy endpoint is already met and whose safety record is clean.
  • Stock-direction (which way do the shares move?): no-edge — confidence none — window 2026-10-19 to 2026-11-03, basis: opens when the abstract publishes and closes one week after the congress ends. Materiality, per rule 27: ../company.md C.2 records this program as meaningful at the programme level and immaterial at the event level, and the call follows the event. Attribution, per rule 36: CONTAMINATED by IMP761’s H2 2026 window, with a quarterly report and the 20-F also due inside the window.
  • Break-even probability 62.9%, range 20.0–120.0% — clearance none — gap evidence: 0 items
  • Cash floor: US$4.37 per ADS
  • Scenario prices: positive US$3.05–US$4.00 · miss US$2.30–US$3.00
  • Commercial ceiling: US$70.70 — positive high allowed up to US$104.46
  • Expected value: US$3.394, +6.05% against spot US$3.20
  • Run-up: No run-up call. Not rule 39: no exit rule resolves after the entry (see Run-up).
  • Settles on the publication of the EFTISARC-NEO HRQoL abstract on the ESMO Congress 2026 website on 2026-10-19 and ePoster 3788eP at the congress. Positive is defined as: the abstract, ePoster or accompanying Immutep release reports health-related quality of life maintained or improved from baseline through the neoadjuvant period, with no statistically significant and no clinically meaningful deterioration (at least 10 points on a 0–100 EORTC QLQ-C30-type global health status scale, or the stated equivalent on the instrument used) in the primary quality-of-life measure reported. A result presented as mixed, a clinically meaningful deterioration on the headline measure, or a withdrawn presentation settles as a miss. The definition is carried word for word in substance from the superseded record, so the two records are scored on the same test.
  • Locked: yes · Settled: no

Program data-quality flags

  • Price-cache splice (named data defect). data/prices/IMMP.json holds two price scales: bars to 2026-09-25 on the old basis (1 ADS = 10 ordinary), bars from 2026-09-29 on the new basis (1 ADS = 200 ordinary). 2026-09-28, the effective date, is a null bar although Nasdaq counted it as a trading day. 2026-09-14 is a lone new-basis bar (6.60, volume 25,415) between two old-basis bars (0.37 and 0.33). The fetch of 2026-10-17 reported that the source now returns the old bars at 20 times their stored values, and the fetcher never overwrites. Handling here: the 52-week range in ../company.md C.4 uses an adjusted copy (old bars × 20, 2026-09-14 left as is); every C.7 event window lies wholly on one side of the change; spot is a new-basis bar; the run-up is withheld for an unrelated reason, so no run-up driver reads the splice. The cache was not repaired: it is outside this lane.
  • Corporate action confirmed from primary sources. The ratio change from 1:10 to 1:200, effective 2026-09-28, is stated in the company’s 6-K of 2026-09-22 [36] and confirmed as completed in the 6-K of 2026-10-14 [50]. Ordinary shares unchanged at 1,473,721,306.
  • The superseded record needs a spot_scale of 20 at settlement. Its spot (US$0.40), scenario prices and run-up entry are on the old basis.
  • Intraday bar frozen in the cache: 2026-08-19 stored at 0.3964 on volume 44,352, against a source close of 0.39.
  • Open Targets answered. Blocked on 2026-08-19 with Rate limit exceeded for client: global; on 2026-10-17 it returned the three entities and a follow-up association query.
  • PubMed’s null-authors bug did not fire. All ten articles returned complete author lists.
  • No EFTISARC-NEO publication in PubMed, seventeen months after the primary endpoint. A real absence, not a connector failure.
  • A cited review contains a factual error. Ibrahim et al. 2023 [40] states that “two LAG-3-directed agents (eftilagimod alpha and relatlimab) have been approved in combination with programmed death-1 (PD-1) inhibitors”. It has not been approved anywhere [29]. The review is cited here only for the class landscape.
  • The catalyst’s endpoint is not registered on NCT06128863, and the instrument is undisclosed, so the settlement definition names a threshold generically.
  • CT.gov lists no investigators for NCT06128863, and the TACTI-004 record (NCT06726265) still reads “active, not recruiting” with a 2027-06 primary completion, seven months after the trial was stopped.
  • No conflict-of-interest statements were retrievable from PubMed for any person in A.2b.
  • Secondary relays. The 2025-10-20 and 2025-11-13 Immutep releases are cited through Benzinga’s relay of the GlobeNewswire text, because GlobeNewswire returned HTTP 403 to a direct read on 2026-10-17.
  • Correction carried into this version: SARC032’s design. The 2026-08-19 version called SARC032 a “randomised Phase 3” and dated its Lancet paper 2024-09-14. The Lancet abstract describes “an open-label, randomised clinical trial” with 143 patients randomised, and PubMed dates it 2024-11-12 [10]. Both are corrected here.

Sources

[1] Immutep and Dr. Reddy’s Laboratories, licensing agreement announcement, 2025-12-08 — https://announcements.asx.com.au/asxpdf/20251208/pdf/06t2zvhhpr4wp1.pdf [2] Atkinson V et al., Eftilagimod alpha plus pembrolizumab in metastatic melanoma, J Immunother Cancer 2020 — https://doi.org/10.1136/jitc-2020-001681 [3] ClinicalTrials.gov, NCT06128863 (EFTISARC-NEO), read 2026-10-17 — https://clinicaltrials.gov/study/NCT06128863 [4] Immutep, FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, 2026-04-15 — https://www.globenewswire.com/news-release/2026/04/15/3274356/0/en/Immutep-Receives-FDA-Orphan-Drug-Designation-for-Eftilagimod-Alfa-in-Soft-Tissue-Sarcoma.html [5] Immutep, FY26 Annual Report including financial statements, Form 6-K Exhibit 99.1, filed 2026-09-02 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526379062/d435000dex991.htm [6] Immutep, Abstract accepted for presentation at ESMO Congress 2026, 2026-07-24 — https://www.immutep.com/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026/ [7] BIO, Informa Pharma Intelligence and QLS Advisors, Clinical Development Success Rates 2011–2020, February 2021 — https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf [8] Immutep, Translational data and pathologic response rates from EFTISARC-NEO at CTOS 2025, 2025-11-13 (secondary relay of the company release) — https://www.benzinga.com/pressreleases/25/11/g48831052/translational-data-and-significant-pathologic-response-rates-from-eftisarc-neo-phase-ii-highlighte [9] Immutep, Focused development strategy for eftilagimod alfa, Form 6-K Exhibit 99.1, 2026-09-11 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526389402/d127093dex991.htm [10] Mowery YM et al., Pembrolizumab, radiation therapy and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032), Lancet 2024 — https://doi.org/10.1016/S0140-6736(24)01812-9 [11] Immutep, TACTI-004 Phase III to be discontinued following futility analysis, 2026-03-13 — https://www.globenewswire.com/news-release/2026/03/13/3255426/0/en/TACTI-004-Phase-III-Study-in-First-Line-NSCLC-to-be-discontinued-following-Futility-Analysis.html [12] Immutep, Efti with radiotherapy and pembrolizumab meets primary endpoint in Phase II for soft tissue sarcoma, 2025-05-27 — https://www.immutep.com/detail/immutep-s-efti-with-radiotherapy-keytruda-r-pembrolizumab-meets-primary-endpoint-in-phase-ii-for-soft-tissue-sarcoma.html [13] Immutep, Positive data from Phase II trial in soft tissue sarcoma presented at CTOS 2024, 2024-11-14 — https://www.immutep.com/detail/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting.html [14] ClinicalTrials.gov, NCT03092323 (SU2C-SARC032) — https://clinicaltrials.gov/study/NCT03092323 [15] ClinicalTrials.gov, NCT06726265 (TACTI-004) — https://clinicaltrials.gov/study/NCT06726265 [16] ClinicalTrials.gov, NCT02614833 (AIPAC) — https://clinicaltrials.gov/study/NCT02614833 [17] ClinicalTrials.gov, NCT03625323 (TACTI-002) — https://clinicaltrials.gov/study/NCT03625323 [18] ClinicalTrials.gov, NCT04811027 (TACTI-003) — https://clinicaltrials.gov/study/NCT04811027 [19] ClinicalTrials.gov, NCT05747794 (AIPAC-003) — https://clinicaltrials.gov/study/NCT05747794 [20] ClinicalTrials.gov, NCT02676869 (TACTI-mel) — https://clinicaltrials.gov/study/NCT02676869 [21] Al-Batran SE et al., Eftilagimod alpha and avelumab in a phase I trial, ESMO Open 2023 — https://doi.org/10.1016/j.esmoop.2023.101623 [22] Wildiers H et al., AIPAC: paclitaxel plus eftilagimod alpha in HR+ metastatic breast cancer, Clin Cancer Res 2024 — https://doi.org/10.1158/1078-0432.CCR-23-1173 [23] PubMed search “eftilagimod”, 10 results, 2026-10-17 — https://pubmed.ncbi.nlm.nih.gov/?term=eftilagimod [24] Immutep, Systemic immune activation with eftilagimod alfa associated with increased overall survival, 2026-05-28 — https://www.globenewswire.com/news-release/2026/05/28/3302799/0/en/systemic-immune-activation-with-eftilagimod-alfa-associated-with-statistically-significant-increased-overall-survival-in-late-stage-cancer-patients.html [25] FDA Purple Book search, read 2026-10-17 — https://purplebooksearch.fda.gov [26] Open Targets Platform, LAG3 (ENSG00000089692) and soft tissue sarcoma (MONDO_0018078) evidence, read 2026-10-17 — https://platform.opentargets.org/evidence/ENSG00000089692/MONDO_0018078 [27] Giri VK, McDermott DF, Zaemes J, The emerging role of LAG-3 targeting in solid malignancies, Cancer 2025 — https://doi.org/10.1002/cncr.35892 [28] DailyMed, KEYTRUDA (pembrolizumab) label, published 2026-07-24 — https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287 [29] ChEMBL, CHEMBL4594557 (eftilagimod alfa), read 2026-10-17 — https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594557/ [30] Forster M et al., Eftilagimod alpha with pembrolizumab in second-line HNSCC, Clin Cancer Res 2024 — https://doi.org/10.1158/1078-0432.CCR-24-0473 [31] Wiśniewska A et al., LAG-3 in (auto)immunity and cancer, Autoimmun Rev 2026 — https://doi.org/10.1016/j.autrev.2026.103992 [32] Immutep, Clinical update in 1st line NSCLC: INSIGHT-003 and TACTI-004, 2026-07-13 — https://www.globenewswire.com/news-release/2026/07/13/3326130/0/en/immutep-provides-clinical-update-in-1st-line-nsclc-positive-mature-overall-survival-data-from-insight-003-and-update-from-tacti-004.html [33] Immutep, Primary endpoint met in EFTISARC-NEO and data presented at ESMO Congress 2025, 2025-10-20 (secondary relay of the company release) — https://www.benzinga.com/pressreleases/25/10/g48299584/primary-endpoint-met-in-eftisarc-neo-phase-ii-evaluating-neoadjuvant-efti-in-soft-tissue-sarcoma-a [34] Czarnecka AM et al. (incl. Teterycz P), Long-term efficacy of radical treatment of clear cell sarcoma, Eur J Surg Oncol 2026 — https://doi.org/10.1016/j.ejso.2026.111485 [35] G-BA, Nutzenbewertungsverfahren zum Wirkstoff Olaratumab (Weichgewebesarkom), decisions 2017-05-18 and 2020-01-16 — https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/268/ [36] Immutep, Change to American Depositary Share ratio, Form 6-K Exhibit 99.1, 2026-09-21 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526397189/d79097dex991.htm [37] O’Byrne K et al., TACTI-004 trial design, Future Oncol 2025 — https://doi.org/10.1080/14796694.2025.2597404 [38] Krebs MG et al., Eftilagimod alpha with pembrolizumab in second-line NSCLC, JTO Clin Res Rep 2024 — https://doi.org/10.1016/j.jtocrr.2024.100725 [39] Immutep, Quarterly Activities Report Q4 FY26, 2026-07-30 — https://www.globenewswire.com/news-release/2026/07/30/3335983/0/en/immutep-quarterly-activities-report-q4-fy26.html [40] Ibrahim R et al., LAG-3 inhibitors: novel immune checkpoint inhibitors, Biomedicines 2023 (contains a factual error; see flags) — https://doi.org/10.3390/biomedicines11071878 [41] NICE, TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma, 2017-08-09 — https://www.nice.org.uk/guidance/ta465 [42] ICER, assessments list, read 2026-10-17 — https://icer.org/assessments/ [43] CMS, Medicare drug price negotiation, read 2026-10-17 — https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation [44] Milliman, Medicare drug price negotiation: Part B dynamics, 2026 (secondary) — https://www.milliman.com/en-GB/insight/medicare-drug-price-negotiation-part-b-dynamics [45] European Commission, Joint clinical assessments, read 2026-10-17 — https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/joint-clinical-assessments_en [46] NICE, TA185: Trabectedin for the treatment of advanced soft tissue sarcoma — https://www.nice.org.uk/guidance/ta185 [47] Taiho Pharmaceutical, Yondelis (trabectedin) listed on the NHI price list, 2015-11-26 — https://taiho.co.jp/en/release/2015/20151126.html [48] Pharmaceutical Technology, Eftilagimod alfa forecast citing GlobalData (secondary; rejected input) — https://www.pharmaceutical-technology.com/data-insights/eftilagimod-alfa-immutep-net-present-value/ [49] ESMO, ESMO Congress 2026, Madrid, 23–27 October 2026 — https://www.esmo.org/meeting-calendar/esmo-congress-2026 [50] Immutep, Regains compliance with Nasdaq minimum bid price requirement, Form 6-K Exhibit 99.1, 2026-10-13 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm [51] IQVIA, Inflection Point: How Clinical Trial Results Impact Biopharma Valuations, May 2024 — https://www.iqvia.com/library/white-papers/how-clinical-trial-results-impact-biopharma-valuations

Sources

    [1] Immutep and Dr. Reddy's Laboratories, licensing agreement announcement, 2025-12-08 — https://announcements.asx.com.au/asxpdf/20251208/pdf/06t2zvhhpr4wp1.pdf [2] Atkinson V et al., Eftilagimod alpha plus pembrolizumab in metastatic melanoma, J Immunother Cancer 2020 — https://doi.org/10.1136/jitc-2020-001681 [3] ClinicalTrials.gov, NCT06128863 (EFTISARC-NEO), read 2026-10-17 — https://clinicaltrials.gov/study/NCT06128863 [4] Immutep, FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, 2026-04-15 — https://www.globenewswire.com/news-release/2026/04/15/3274356/0/en/Immutep-Receives-FDA-Orphan-Drug-Designation-for-Eftilagimod-Alfa-in-Soft-Tissue-Sarcoma.html [5] Immutep, FY26 Annual Report including financial statements, Form 6-K Exhibit 99.1, filed 2026-09-02 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526379062/d435000dex991.htm [6] Immutep, Abstract accepted for presentation at ESMO Congress 2026, 2026-07-24 — https://www.immutep.com/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026/ [7] BIO, Informa Pharma Intelligence and QLS Advisors, Clinical Development Success Rates 2011–2020, February 2021 — https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf [8] Immutep, Translational data and pathologic response rates from EFTISARC-NEO at CTOS 2025, 2025-11-13 (secondary relay of the company release) — https://www.benzinga.com/pressreleases/25/11/g48831052/translational-data-and-significant-pathologic-response-rates-from-eftisarc-neo-phase-ii-highlighte [9] Immutep, Focused development strategy for eftilagimod alfa, Form 6-K Exhibit 99.1, 2026-09-11 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526389402/d127093dex991.htm [10] Mowery YM et al., Pembrolizumab, radiation therapy and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032), Lancet 2024 — https://doi.org/10.1016/S0140-6736(24)01812-9 [11] Immutep, TACTI-004 Phase III to be discontinued following futility analysis, 2026-03-13 — https://www.globenewswire.com/news-release/2026/03/13/3255426/0/en/TACTI-004-Phase-III-Study-in-First-Line-NSCLC-to-be-discontinued-following-Futility-Analysis.html [12] Immutep, Efti with radiotherapy and pembrolizumab meets primary endpoint in Phase II for soft tissue sarcoma, 2025-05-27 — https://www.immutep.com/detail/immutep-s-efti-with-radiotherapy-keytruda-r-pembrolizumab-meets-primary-endpoint-in-phase-ii-for-soft-tissue-sarcoma.html [13] Immutep, Positive data from Phase II trial in soft tissue sarcoma presented at CTOS 2024, 2024-11-14 — https://www.immutep.com/detail/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting.html [14] ClinicalTrials.gov, NCT03092323 (SU2C-SARC032) — https://clinicaltrials.gov/study/NCT03092323 [15] ClinicalTrials.gov, NCT06726265 (TACTI-004) — https://clinicaltrials.gov/study/NCT06726265 [16] ClinicalTrials.gov, NCT02614833 (AIPAC) — https://clinicaltrials.gov/study/NCT02614833 [17] ClinicalTrials.gov, NCT03625323 (TACTI-002) — https://clinicaltrials.gov/study/NCT03625323 [18] ClinicalTrials.gov, NCT04811027 (TACTI-003) — https://clinicaltrials.gov/study/NCT04811027 [19] ClinicalTrials.gov, NCT05747794 (AIPAC-003) — https://clinicaltrials.gov/study/NCT05747794 [20] ClinicalTrials.gov, NCT02676869 (TACTI-mel) — https://clinicaltrials.gov/study/NCT02676869 [21] Al-Batran SE et al., Eftilagimod alpha and avelumab in a phase I trial, ESMO Open 2023 — https://doi.org/10.1016/j.esmoop.2023.101623 [22] Wildiers H et al., AIPAC: paclitaxel plus eftilagimod alpha in HR+ metastatic breast cancer, Clin Cancer Res 2024 — https://doi.org/10.1158/1078-0432.CCR-23-1173 [23] PubMed search "eftilagimod", 10 results, 2026-10-17 — https://pubmed.ncbi.nlm.nih.gov/?term=eftilagimod [24] Immutep, Systemic immune activation with eftilagimod alfa associated with increased overall survival, 2026-05-28 — https://www.globenewswire.com/news-release/2026/05/28/3302799/0/en/systemic-immune-activation-with-eftilagimod-alfa-associated-with-statistically-significant-increased-overall-survival-in-late-stage-cancer-patients.html [25] FDA Purple Book search, read 2026-10-17 — https://purplebooksearch.fda.gov [26] Open Targets Platform, LAG3 (ENSG00000089692) and soft tissue sarcoma (MONDO_0018078) evidence, read 2026-10-17 — https://platform.opentargets.org/evidence/ENSG00000089692/MONDO_0018078 [27] Giri VK, McDermott DF, Zaemes J, The emerging role of LAG-3 targeting in solid malignancies, Cancer 2025 — https://doi.org/10.1002/cncr.35892 [28] DailyMed, KEYTRUDA (pembrolizumab) label, published 2026-07-24 — https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287 [29] ChEMBL, CHEMBL4594557 (eftilagimod alfa), read 2026-10-17 — https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594557/ [30] Forster M et al., Eftilagimod alpha with pembrolizumab in second-line HNSCC, Clin Cancer Res 2024 — https://doi.org/10.1158/1078-0432.CCR-24-0473 [31] Wiśniewska A et al., LAG-3 in (auto)immunity and cancer, Autoimmun Rev 2026 — https://doi.org/10.1016/j.autrev.2026.103992 [32] Immutep, Clinical update in 1st line NSCLC: INSIGHT-003 and TACTI-004, 2026-07-13 — https://www.globenewswire.com/news-release/2026/07/13/3326130/0/en/immutep-provides-clinical-update-in-1st-line-nsclc-positive-mature-overall-survival-data-from-insight-003-and-update-from-tacti-004.html [33] Immutep, Primary endpoint met in EFTISARC-NEO and data presented at ESMO Congress 2025, 2025-10-20 (secondary relay of the company release) — https://www.benzinga.com/pressreleases/25/10/g48299584/primary-endpoint-met-in-eftisarc-neo-phase-ii-evaluating-neoadjuvant-efti-in-soft-tissue-sarcoma-a [34] Czarnecka AM et al. (incl. Teterycz P), Long-term efficacy of radical treatment of clear cell sarcoma, Eur J Surg Oncol 2026 — https://doi.org/10.1016/j.ejso.2026.111485 [35] G-BA, Nutzenbewertungsverfahren zum Wirkstoff Olaratumab (Weichgewebesarkom), decisions 2017-05-18 and 2020-01-16 — https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/268/ [36] Immutep, Change to American Depositary Share ratio, Form 6-K Exhibit 99.1, 2026-09-21 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526397189/d79097dex991.htm [37] O'Byrne K et al., TACTI-004 trial design, Future Oncol 2025 — https://doi.org/10.1080/14796694.2025.2597404 [38] Krebs MG et al., Eftilagimod alpha with pembrolizumab in second-line NSCLC, JTO Clin Res Rep 2024 — https://doi.org/10.1016/j.jtocrr.2024.100725 [39] Immutep, Quarterly Activities Report Q4 FY26, 2026-07-30 — https://www.globenewswire.com/news-release/2026/07/30/3335983/0/en/immutep-quarterly-activities-report-q4-fy26.html [40] Ibrahim R et al., LAG-3 inhibitors: novel immune checkpoint inhibitors, Biomedicines 2023 (contains a factual error; see flags) — https://doi.org/10.3390/biomedicines11071878 [41] NICE, TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma, 2017-08-09 — https://www.nice.org.uk/guidance/ta465 [42] ICER, assessments list, read 2026-10-17 — https://icer.org/assessments/ [43] CMS, Medicare drug price negotiation, read 2026-10-17 — https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation [44] Milliman, Medicare drug price negotiation: Part B dynamics, 2026 (secondary) — https://www.milliman.com/en-GB/insight/medicare-drug-price-negotiation-part-b-dynamics [45] European Commission, Joint clinical assessments, read 2026-10-17 — https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/joint-clinical-assessments_en [46] NICE, TA185: Trabectedin for the treatment of advanced soft tissue sarcoma — https://www.nice.org.uk/guidance/ta185 [47] Taiho Pharmaceutical, Yondelis (trabectedin) listed on the NHI price list, 2015-11-26 — https://taiho.co.jp/en/release/2015/20151126.html [48] Pharmaceutical Technology, Eftilagimod alfa forecast citing GlobalData (secondary; rejected input) — https://www.pharmaceutical-technology.com/data-insights/eftilagimod-alfa-immutep-net-present-value/ [49] ESMO, ESMO Congress 2026, Madrid, 23–27 October 2026 — https://www.esmo.org/meeting-calendar/esmo-congress-2026 [50] Immutep, Regains compliance with Nasdaq minimum bid price requirement, Form 6-K Exhibit 99.1, 2026-10-13 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm [51] IQVIA, Inflection Point: How Clinical Trial Results Impact Biopharma Valuations, May 2024 — https://www.iqvia.com/library/white-papers/how-clinical-trial-results-impact-biopharma-valuations